---
title: "Azetukalner (XEN1101) in Focal onset seizures: Product information and disease description"
description: "Formulary evidence on Azetukalner (XEN1101) in Focal onset seizures: Product information and disease description. Covers Product description and Place of product in therapy. 264 evidence topics quoted from 141 sources."
canonical: "https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/product-information-and-disease-description"
published: "2026-09-21T21:41:53-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Azetukalner (XEN1101) in Focal onset seizures: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Regulatory status: Under review; NDA submitted September 2026

> “VANCOUVER, BC and BOSTON, MA, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced it has submitted a New Drug Application (NDA) for azetukalner in focal seizures (FS) to the U.S. Food and Drug Administration (FDA).”
> “We are very pleased to announce completion of the NDA submission for azetukalner in focal seizures in epilepsy.”

Source: [Xenon Pharmaceuticals NDA submission release (2026)](https://www.globenewswire.com/news-release/2026/09/17/3364364/33485/en/xenon-announces-azetukalner-nda-submission-to-fda-for-focal-seizures-and-provides-update-on-psychiatry-clinical-program.html)

<a id="topic-2.1.1-2"></a>

##### Launch

No evidence found.

<a id="topic-2.1.1-3"></a>

##### Investigational status: no approved product

> “The Company has no products approved for sale and has not generated any revenue from product sales.”

Source: [Xenon Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1582313/000119312526338244/xene-20260630.htm)

<a id="topic-2.1.1-4"></a>

##### Pre-NDA meeting and planned submission quarter

> “We remain on track to submit our New Drug Application (NDA) for azetukalner in FOS in the third quarter of 2026, having completed a pre-NDA meeting with the U.S. Food and Drug Administration (FDA).”

Source: [Xenon Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1582313/000119312526338244/xene-20260630.htm)

<a id="topic-2.1.1-5"></a>

##### Clinical basis of the New Drug Application

> “The NDA submission is based on positive clinical data from two global, randomized, double-blind, placebo-controlled trials for azetukalner in focal seizures, including the Phase 2b X-TOLE study and Phase 3 X-TOLE2 study. Across the two studies, treatment with all four doses of azetukalner demonstrated a statistically significant reduction from baseline in monthly seizure frequency compared with placebo, and azetukalner was generally well-tolerated with a consistent safety profile observed in both studies. These safety results are comparable with the long-term safety observed in the X-TOLE open label extension (OLE) study, with the entire epilepsy program generating more than 1,500 patient-years of safety and exposure data.”

Source: [Xenon Pharmaceuticals NDA submission release (2026)](https://www.globenewswire.com/news-release/2026/09/17/3364364/33485/en/xenon-announces-azetukalner-nda-submission-to-fda-for-focal-seizures-and-provides-update-on-psychiatry-clinical-program.html)

<a id="topic-2.1.1-6"></a>

##### Studies supporting submissions outside the United States and in a second seizure type

> “The ongoing Phase 3 X-TOLE3 and X-ACKT studies of azetukalner in focal seizures and primary generalized tonic-clonic seizures (PGTCS), respectively, continue to enroll patients to support expansion of use across seizure types and global regions.”

Source: [Xenon Pharmaceuticals NDA submission release (2026)](https://www.globenewswire.com/news-release/2026/09/17/3364364/33485/en/xenon-announces-azetukalner-nda-submission-to-fda-for-focal-seizures-and-provides-update-on-psychiatry-clinical-program.html)

<a id="topic-2.1.1-7"></a>

##### Japanese regulatory interaction

> “In support of a potential regulatory submission in Japan, Xenon has completed an ethnobridging study and shared the results in a recent meeting with Japan’s Pharmaceutical and Medical Devices Agency (PMDA). Xenon has aligned with PMDA to enroll approximately 60 of the planned 360 X-TOLE3 participants in Japan.”

Source: [Xenon Pharmaceuticals J.P. Morgan Healthcare Conference release (2026)](https://www.globenewswire.com/news-release/2026/01/12/3216905/0/en/xenon-outlines-key-upcoming-milestones-at-the-2026-j-p-morgan-healthcare-conference.html)

<a id="topic-2.1.1-8"></a>

##### First-in-class positioning if approved

> “If approved, azetukalner would be the only KV7 potassium channel opener available for the treatment of epilepsy.”

Source: [Xenon Pharmaceuticals X-TOLE2 topline release (2026)](https://www.globenewswire.com/news-release/2026/03/09/3251686/33485/en/Xenon-Announces-Positive-Topline-Data-from-Phase-3-X-TOLE2-Study-of-Azetukalner-in-Focal-Onset-Seizures-FOS.html)

<a id="topic-2.1.1-9"></a>

##### Commercial readiness activities

> “With a strong body of clinical evidence from two large placebo-controlled trials and more than 800 patient-years of exposure data, we are focusing next on submitting our new drug application to the FDA later this year, as well as advancing our commercial-readiness activities in anticipation of our first commercial launch.”

Source: [Xenon Pharmaceuticals X-TOLE2 topline release (2026)](https://www.globenewswire.com/news-release/2026/03/09/3251686/33485/en/Xenon-Announces-Positive-Topline-Data-from-Phase-3-X-TOLE2-Study-of-Azetukalner-in-Focal-Onset-Seizures-FOS.html)

<a id="topic-2.1.1-10"></a>

##### FDA expedited program designations, filing acceptance, and action date

No evidence found.

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Manufacturer: Xenon Pharmaceuticals

> “Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon's lead molecule, azetukalner, is a novel, potent KV7 potassium channel opener in late-stage clinical development for the treatment of epilepsy, major depressive disorder and bipolar depression.”

Source: [Xenon Pharmaceuticals NDA submission release (2026)](https://www.globenewswire.com/news-release/2026/09/17/3364364/33485/en/xenon-announces-azetukalner-nda-submission-to-fda-for-focal-seizures-and-provides-update-on-psychiatry-clinical-program.html)

<a id="topic-2.1.2.1-2"></a>

###### Development history and prior product codes

> “Originally described in a patent by Valeant Pharmaceuticals in 2008, azetukalner was acquired by First-Order Pharmaceuticals in 2015 and later obtained by Xenon Pharmaceuticals in 2017. It was formerly known as encukalner, XEN1101, 1OP-2198, or VRX621698”

Source: [Rosendahl et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13330554/)

<a id="topic-2.1.2.1-3"></a>

###### Therapeutic class: KV7 potassium channel opener

> “Azetukalner is a novel, potent KV7 potassium channel opener currently in development for the treatment of epilepsy, major depressive disorder and bipolar depression. It represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development.”

Source: [Xenon Pharmaceuticals NDA submission release (2026)](https://www.globenewswire.com/news-release/2026/09/17/3364364/33485/en/xenon-announces-azetukalner-nda-submission-to-fda-for-focal-seizures-and-provides-update-on-psychiatry-clinical-program.html)

<a id="topic-2.1.2.1-4"></a>

###### Molecular target and seizure type addressed

> “XEN1101 is a novel, small-molecule, selective Kv7.2/Kv7.3 potassium channel opener being developed for the treatment of FOSs, the most common type of seizures experienced by individuals with epilepsy.”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-2.1.2.1-5"></a>

###### Brand name

No evidence found.

Additional sources: [WHO Drug Information Recommended INN List 90 (2023)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/rl90.pdf)

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Oral capsule formulation used in the Phase 2b study

> “This was a multicenter, randomized, double-blind, parallel-group, dose-ranging, placebo-controlled adjunctive-therapy clinical trial in which XEN1101 was administered once daily with food as a 10-, 20-, or 25-mg oral capsule.”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-2.1.2.2-2"></a>

###### Immediate-release capsules used in Phase 1

> “After single doses ranging from 5 to 30 mg (immediate-release capsules) administered in the fasting state, peak plasma azetukalner concentrations are achieved at 3.2–4.5 h on average.”

Source: [Perucca and Taglialatela (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850491/)

<a id="topic-2.1.2.2-3"></a>

###### Strengths evaluated in the Phase 3 focal seizure studies

> “The completed X-TOLE2 study and the ongoing X-TOLE3 study were both designed as multicenter, randomized, double-blind, placebo-controlled studies to evaluate the clinical efficacy, safety, and tolerability of 15 mg or 25 mg of azetukalner administered orally with food as adjunctive treatment in approximately 360 patients per study with FOS.”

Source: [Xenon Pharmaceuticals NDA submission release (2026)](https://www.globenewswire.com/news-release/2026/09/17/3364364/33485/en/xenon-announces-azetukalner-nda-submission-to-fda-for-focal-seizures-and-provides-update-on-psychiatry-clinical-program.html)

<a id="topic-2.1.2.2-4"></a>

###### Registry record of the dosage form

> “XEN1101 Capsules”

Source: [ClinicalTrials.gov NCT05614063](https://clinicaltrials.gov/study/NCT05614063)

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

<a id="topic-2.1.2.3-1"></a>

###### Announced price for azetukalner

No evidence found.

<a id="topic-2.1.2.3-2"></a>

###### No approved product and no product revenue

> “We have no products approved for commercial sale and have not generated any revenue from product sales to date, and we will continue to incur significant research and development and other expenses related to our clinical development and ongoing operations.”
> “Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval.”
> “In order to obtain and maintain acceptable reimbursement levels and access for patients at copay levels that are reasonable and customary, we may have to offer discounts or rebates from list prices or to implement other unfavorable pricing modifications.”

Source: [Xenon Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1582313/000119312526076650/xene-20251231.htm)

<a id="topic-2.1.2.3-3"></a>

###### Branded adjunctive antiseizure medication comparators: United States National Average Drug Acquisition Cost, week of 16 September 2026

| Product and strength | Quoted record description | Quoted acquisition cost per unit | Quoted effective date |
| --- | --- | --- | --- |
| Cenobamate 200 mg tablet | “XCOPRI 200 MG TABLET” | “39.86819” | “2026-08-19” |
| Brivaracetam 100 mg tablet | “BRIVIACT 100 MG TABLET” | “24.07624” | “2026-08-19” |
| Perampanel 12 mg tablet | “FYCOMPA 12 MG TABLET” | “39.07764” | “2026-08-19” |

Source: [Medicaid.gov National Average Drug Acquisition Cost (2026)](https://data.medicaid.gov/api/1/datastore/query/fbb83258-11c7-47f5-8b18-5f8e79f7e704/0?conditions%5B0%5D%5Bproperty%5D=ndc_description&conditions%5B0%5D%5Boperator%5D=in&conditions%5B0%5D%5Bvalue%5D%5B%5D=XCOPRI%20200%20MG%20TABLET&conditions%5B0%5D%5Bvalue%5D%5B%5D=BRIVIACT%20100%20MG%20TABLET&conditions%5B0%5D%5Bvalue%5D%5B%5D=FYCOMPA%2012%20MG%20TABLET&conditions%5B1%5D%5Bproperty%5D=as_of_date&conditions%5B1%5D%5Boperator%5D=%3D&conditions%5B1%5D%5Bvalue%5D=2026-09-16&limit=10&properties%5B%5D=ndc_description&properties%5B%5D=ndc&properties%5B%5D=nadac_per_unit&properties%5B%5D=pricing_unit&properties%5B%5D=effective_date&properties%5B%5D=as_of_date)

<a id="topic-2.1.2.3-4"></a>

###### United States brand and generic antiseizure medication price levels, 2013 to 2023

> “This study utilized National Average Drug Acquisition Cost (NADAC) data from November 2013 to July 2023.”
> “From 2013-2016 to 2020-2023, accounting for standard deviations (SD), the average price of brand-name ASMs increased from $8.71 (SD 5.9) to $15.43 (SD 10.7), while generic ASMs saw a slight decrease from $1.39 (SD 1.8) to $1.26 (SD 1.6).”
> “Consequently, the price gap between brand-name and generic ASMs surged from 1452.39 % to 3399.26 %.”

Source: [Javarayee et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39306895/)

<a id="topic-2.1.2.3-5"></a>

###### Cenobamate list price, United Kingdom

> “Titration packs of 14 to 28 tablets are available in different doses ranging from 12.5 mg to 200 mg and costing between £85.54 to £165.62 per pack.”
> “Maintenance packs of 28 tablets are available in doses ranging from 50 mg to 200 mg costing £91 to £182 per pack.”
> “Estimated cost for the maintenance phase of treatment is £206 per person every 28 days (£7.37 per day).”

Source: [NICE technology appraisal guidance TA753 information about cenobamate (2021)](https://www.nice.org.uk/guidance/ta753/chapter/2-Information-about-cenobamate)

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### Mechanistic classification

> “On the basis of these data, azetulkalner can be classified as a selective opener of neuronal Kv7.2/7.3 channels, with no effects on cardiac (Kv7.1) channels.”

Source: [Perucca and Taglialatela (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850491/)

<a id="topic-2.1.2.4-2"></a>

###### AHFS classification

No evidence found.

Additional sources: [WHO Drug Information Recommended INN List 90 (2023)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/rl90.pdf)

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Indication sought in the United States New Drug Application

> “today announced it has submitted a New Drug Application (NDA) for azetukalner in focal seizures (FS) to the U.S. Food and Drug Administration (FDA).”

Source: [Xenon Pharmaceuticals NDA submission release (2026)](https://www.globenewswire.com/news-release/2026/09/17/3364364/33485/en/xenon-announces-azetukalner-nda-submission-to-fda-for-focal-seizures-and-provides-update-on-psychiatry-clinical-program.html)

<a id="topic-2.1.2.5-2"></a>

###### Indication described at the Phase 3 readout

> “Xenon plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the treatment of focal onset seizures in the third quarter of 2026.”

Source: [Xenon Pharmaceuticals X-TOLE2 topline release (2026)](https://www.globenewswire.com/news-release/2026/03/09/3251686/33485/en/Xenon-Announces-Positive-Topline-Data-from-Phase-3-X-TOLE2-Study-of-Azetukalner-in-Focal-Onset-Seizures-FOS.html)

<a id="topic-2.1.2.5-3"></a>

###### Adjunctive use in adults, as studied in the registration trial

> “A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures”

Source: [ClinicalTrials.gov NCT05614063](https://clinicaltrials.gov/study/NCT05614063)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Potassium channel opening and neuronal hyperpolarization

> “Azetukalner is designed to open potassium channels in the central nervous system, allowing potassium ions to flow and hyperpolarizing neurons. This process helps reduce excessive neuronal firing, which is a key contributor to several neurologic and psychiatric disorders.”

Source: [Xenon Pharmaceuticals NDA submission release (2026)](https://www.globenewswire.com/news-release/2026/09/17/3364364/33485/en/xenon-announces-azetukalner-nda-submission-to-fda-for-focal-seizures-and-provides-update-on-psychiatry-clinical-program.html)

<a id="topic-2.1.2.6.1-2"></a>

###### Stabilization of the open channel state

> “By stabilizing the open state of these channels, it promotes a hyperpolarized resting membrane potential, thereby reducing rapid action potential spiking.”

Source: [Rosendahl et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13330554/)

<a id="topic-2.1.2.6.1-3"></a>

###### In vitro potency at KV7.2 and KV7.2/7.3 channels

> “In these systems, azetukalner was found to activate Kv7.2 channels with half-maximal effective concentrations (EC50) of 11 and 15 nM, respectively. In a Xenopus oocyte expression system, azetukalner activated channels Kv7.2, Kv7.5, Kv7.4, and Kv7.2/7.3 heteromer with EC50 values of 0.45, 0.35, 0.63, and 0.35 µM, respectively”

Source: [Perucca and Taglialatela (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850491/)

<a id="topic-2.1.2.6.1-4"></a>

###### Subtype selectivity within the KV7 family

> “In in vitro studies in CHO cell lines expressing heteromeric Kv7.2/7.3 and Kv7.3/7.5 channels and homomeric Kv7.4 channels, azetukalner showed 3.4-fold greater selectivity for Kv7.2/7.3 over Kv7.3/7.5 and Kv7.4 channels, with EC50 values of 27 nM versus 94 nM and 113 nM, respectively”

Source: [Perucca and Taglialatela (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850491/)

<a id="topic-2.1.2.6.1-5"></a>

###### Selectivity over other ion channels and the GABA system

> “Azetukalner reportedly exerts no activity on other ion channels or the GABA system at concentrations > 100-fold greater than those active on Kv7.2 channels”

Source: [Perucca and Taglialatela (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850491/)

<a id="topic-2.1.2.6.1-6"></a>

###### Relative rather than absolute selectivity

> “Reported selectivity is subtype-relative rather than absolute: in heterologous expression assays azetukalner is approximately fourfold more potent at KV7.2/7.3 than at KV7.3/7.5 or KV7.4, with screening selectivity over unrelated channels and receptors reported as greater than 100-fold, including absence of the GABAA activity seen with retigabine.”

Source: [Martins (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13510719/)

<a id="topic-2.1.2.6.1-7"></a>

###### Potency relative to ezogabine

> “In studies with human embryonic kidney (HEK) cells expressing Kv7.2/7.3 channels, azetukalner (EC50, 42 nM) was 20 times more potent than ezogabine (EC50, 920 nM) in causing an approximate 40 mV leftward (negative) shift in the half-maximal voltage of channel activation, while causing a similar increase in maximal conductance”

Source: [Perucca and Taglialatela (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850491/)

<a id="topic-2.1.2.6.1-8"></a>

###### Structural difference from ezogabine

> “The novel structure differs from that of ezogabine.”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-2.1.2.6.1-9"></a>

###### Structural basis for bypassing the pigment-forming pathway

> “It was designed to bypass the pigment-forming pathway associated with retigabine”
> “Unlike retigabine, which bears a secondary aromatic amino group, the amino functionality of azetukalner is incorporated within a tetrahydroisoquinoline ring system, which sterically and electronically constrains the nitrogen atom and prevents 1 from participating in oxidative dimerization.”

Source: [Rosendahl et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13330554/)

Additional sources: [Lattanzi et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38571335/)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Preclinical antiseizure activity in rodent seizure models

> “In the MES test, azetukalner has ED50 values of 1.1 mg/kg in rats at 60 min after per os (p.o.) dosing, and 2.2 mg/kg in mice at 120 min after i.p. dosing. In mice, azetukalner is also effective in protecting against seizures induced by subcutaneous (s.c.) pentylenetetrazole, s.c. picrotoxin, s.c. bicuculline, and 6 Hz stimulation, with ED50 values < 10 mg/kg i.p., which correspond to a > 3–19-fold greater potency compared with ezogabine (Table 2 )”

Source: [Perucca and Taglialatela (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850491/)

<a id="topic-2.1.2.6.2-2"></a>

###### Transcranial magnetic stimulation biomarkers of cortical excitability

> “Consistent with previous TMS investigations of antiepileptic drugs (AEDs) targeting ion channels, the amplitude of TEPs occurring at early (15–55 msec after TMS) and at late (150–250 msec after TMS) latencies were significantly suppressed from baseline by 20 mg of XEN1101. Furthermore, the RMT showed a significant time-dependent increase that correlated with the XEN1101 plasma concentration.”

Source: [Premoli et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6856596/)

<a id="topic-2.1.2.6.2-3"></a>

###### Concentration-effect relationship for resting motor threshold

> “Mean plasma azetukalner concentrations (± SD) at 2, 4, and 6 h after dosing were 15.7 ± 21.5 ng/mL, 30.2 ± 21.9 ng/mL, and 42.1 ± 19.1 ng/mL, respectively. At the time of individual peak drug concentrations, plasma azetukalner levels correlated significantly with changes in RMTs, but not with changes in TEPs.”

Source: [Perucca and Taglialatela (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850491/)

<a id="topic-2.1.2.6.2-4"></a>

###### Use of the transcranial magnetic stimulation study for target engagement and dose selection

> “In addition, data from a Phase 1b transcranial magnetic stimulation, or TMS, study – which was designed to assess azetukalner’s ability and potency to modulate cortical excitability – demonstrated activity in the target central nervous system, or CNS, tissue and helped inform dose selection for our Phase 2b clinical study.”

Source: [Xenon Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1582313/000119312526076650/xene-20251231.htm)

<a id="topic-2.1.2.6.2-5"></a>

###### In vivo additive effects with other antiseizure medications

> “Additionally, a new poster highlighting the mechanistic characterization of azetukalner will also be presented, including KV7 binding, enhanced channel opening, and rational polytherapy potential. This poster will include in vivo data demonstrating the potential additive effects of azetukalner when used in combination with commonly prescribed antiseizure medications (ASMs), reinforcing its opportunity to enhance seizure control through the application of rational polytherapy in clinical practice.”

Source: [Xenon Pharmaceuticals EEC 2026 release (2026)](https://www.globenewswire.com/news-release/2026/08/26/3351670/33485/en/xenon-to-highlight-phase-3-x-tole2-clinical-data-and-rational-polytherapy-potential-for-azetukalner-at-eec-2026.html)

Additional sources: [ClinicalTrials.gov NCT03468725](https://clinicaltrials.gov/study/NCT03468725)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Absorption and time to peak concentration

> “After single doses ranging from 5 to 30 mg (immediate-release capsules) administered in the fasting state, peak plasma azetukalner concentrations are achieved at 3.2–4.5 h on average. Thereafter, the drug concentration declines with a biphasic profile. Azetukalner AUC increases about 1.8-fold after co-administration with food”

Source: [Perucca and Taglialatela (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850491/)

<a id="topic-2.1.2.6.3-2"></a>

###### Food effect and dose proportionality

> “Absorption in the fed state was relatively slow, with peak drug concentrations occurring at 4–6 h after dosing. When azetukalner is administered in the fasting state, exposure is less than dose proportional. However, after 10 days of once-daily (q.d.) dosing with food, exposure increases proportionally with dose”

Source: [Perucca and Taglialatela (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850491/)

<a id="topic-2.1.2.6.3-3"></a>

###### Half-life and steady state

> “The half-life of azetukalner is about 1–2 days, which implies a modest (about 25%) peak-to-trough fluctuation in serum drug concentration on a q.d. dosing schedule”
> “After multiple dosing, azetukalner elimination shows a late terminal phase with an average half-life of 4–10 days”
> “Steady state (defined as no statistical difference between trough levels on successive days) is reached after 7–10 days, even though complete steady state is expected to occur after about 3 weeks”

Source: [Perucca and Taglialatela (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850491/)

<a id="topic-2.1.2.6.3-4"></a>

###### Terminal half-life supporting once-daily dosing without titration

> “The pharmacokinetic properties of XEN1101, including a long terminal elimination half-life (approximately 10 days), support once-daily oral dosing without the need for titration at initiation of dosing or tapering at termination of dosing.”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-2.1.2.6.3-5"></a>

###### Phase 1 single- and multiple-ascending-dose results

> “Single- and multiple-ascending-dose studies were conducted in healthy volunteers to evaluate PK and tolerability, including an evaluation of food effects. Testing included single doses of 5 mg, 15 mg, 20 mg, and 30 mg, as well as multiple doses of 15 mg once daily for 7 days. Key PK findings revealed peak plasma concentrations (Cmax) of 31.5 ng/mL (20 mg) and 35.5 ng/mL (30 mg), with corresponding half-lives of 41 h and 63.4 h. Elimination followed a biphasic pattern, characterized by a functional half-life of 1–2 days and a terminal half-life exceeding 5 days.”

Source: [Rosendahl et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13330554/)

<a id="topic-2.1.2.6.3-6"></a>

###### Metabolism and elimination

> “After 10 days of dosing at 25 mg q.d., only 0.01% of the administered dose is excreted in urine as unchanged drug over a 24 h collection period, indicating that azetukalner renal clearance is negligible”
> “Azetukalner is cleared by CYP3A4-mediated metabolism, with other CYP enzymes (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6) playing little or no role”
> “A major oxidative metabolite detected in plasma at concentrations of approximately 20% of those of the parent drug has been found to be inactive on Kv7 channels after preliminary testing”

Source: [Perucca and Taglialatela (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850491/)

Additional sources: [ClinicalTrials.gov NCT03340220](https://clinicaltrials.gov/study/NCT03340220); [ClinicalTrials.gov NCT04952467](https://clinicaltrials.gov/study/NCT04952467)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

<a id="topic-2.1.2.7.1-1"></a>

###### FDA-approved prescribing information, contraindications, and boxed warnings

No evidence found.

<a id="topic-2.1.2.7.1-2"></a>

###### Absence of tissue discoloration in the Phase 2b study

> “No TEAEs of tissue discoloration were reported. Two nonserious TEAEs of urinary retention were reported in the active treatment groups, 1 of which required a dose reduction; both patients continued to receive the study medication with no other changes or interventions, including no need for catheterization.”
> “There were no cardiovascular signals of concern in electrocardiograms or vital signs, no allergic skin rashes, and no deaths in the study. Urinary problems were infrequent and mild; no catheterization was required. Moreover, tissue discoloration was not observed in this limited duration trial nor in an interim analysis of the ongoing 5-year, open-label extension study.”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-2.1.2.7.1-3"></a>

###### Urinary retention during long-term open-label treatment

> “Three participants reported urinary retention, 1 reported it as mild and 2 as moderate; no dose changes were made in any case.”
> “Serious AEs were infrequent at 12.7%, as were TEAEs related to urinary retention (1.1%), which have been reported with the use of KV7 channel openers.”

Source: [French et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12014913/)

<a id="topic-2.1.2.7.1-4"></a>

###### Urinary retention as a possible class effect of KV7 openers

> “Urinary retention has been reported in a small minority of patients receiving chronic treatment with ezogabine and azetukalner”
> “urinary retention may be considered a class effect of these medications.”

Source: [Perucca and Taglialatela (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850491/)

<a id="topic-2.1.2.7.1-5"></a>

###### Absence of the ophthalmological and pigmentary pattern seen with retigabine

> “However, azetukalner lacks the recognizable pattern of drug-induced organ toxicity, specifically the urinary retention and ophthalmological abnormalities (e.g., retinal pigmentation and visual acuity changes), that limited the clinical use of retigabine”

Source: [Rosendahl et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13330554/)

<a id="topic-2.1.2.7.1-6"></a>

###### Absence of the phenazinium dimers implicated in ezogabine pigmentation

> “Azetukalner lacks a secondary aniline structure and reportedly does not generate the phenazinium dimers considered to be responsible for ezogabine-induced pigmentation”

Source: [Perucca and Taglialatela (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850491/)

<a id="topic-2.1.2.7.1-7"></a>

###### Central nervous system adverse events

> “The most common (>10%) TEAEs across all XEN1101 dose groups were dizziness (24.6%), somnolence (15.6%), and fatigue (10.9%).”
> “The adverse event of confusional state was reported in 4.7% of the treated groups (2.2% receiving 10 mg, 5.9% receiving 20 mg, and 5.3% receiving 25 mg) and in 0.9% of the placebo group. No allergic rashes occurred.”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-2.1.2.7.1-8"></a>

###### Neuropsychiatric adverse events observed in the psychiatry studies

> “In addition, the Company announced today that it has implemented a voluntary pause on enrollment for new patients in its ongoing clinical studies in major depressive disorder (MDD) and bipolar depression (BPD), following an analysis of neuropsychiatric adverse events in these studies. Participants currently enrolled in the randomized controlled psychiatry studies and associated OLE studies will continue on study. The observed events, the rate of these events and their severity, are consistent with the known safety and tolerability profile of azetukalner and its mechanism; however, such adverse events had not previously been seen in the Phase 2 X‑NOVA clinical study in MDD.”
> “This voluntary action does not impact ongoing epilepsy studies.”

Source: [Xenon Pharmaceuticals NDA submission release (2026)](https://www.globenewswire.com/news-release/2026/09/17/3364364/33485/en/xenon-announces-azetukalner-nda-submission-to-fda-for-focal-seizures-and-provides-update-on-psychiatry-clinical-program.html)

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Adolescents in the generalized tonic-clonic seizure and open-label studies

> “A similar trial ( NCT05667142 ) is being conducted in patients with generalized tonic-clonic seizures, assessing doses of 25 mg q.d. (participants aged ≥ 18 years) and 15 mg or 25 mg q.d (participants aged from 12 to < 18 years).”

Source: [Perucca and Taglialatela (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850491/)

<a id="topic-2.1.2.8-2"></a>

###### Age eligibility in the Phase 3 open-label extension

> “This study will evaluate the long term safety, tolerability, pharmacokinetics (PK), and efficacy of XEN1101 in subjects with Focal Onset Seizures (FOS) or Primary Generalized Tonic-Clonic Seizures (PGTCS) for the treatment of seizures for up to 6 years.”

Source: [ClinicalTrials.gov NCT05718817](https://clinicaltrials.gov/study/NCT05718817)

<a id="topic-2.1.2.8-3"></a>

###### Negligible renal elimination

> “After 10 days of dosing at 25 mg q.d., only 0.01% of the administered dose is excreted in urine as unchanged drug over a 24 h collection period, indicating that azetukalner renal clearance is negligible”

Source: [Perucca and Taglialatela (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850491/)

<a id="topic-2.1.2.8-4"></a>

###### Hepatic impairment, renal impairment, pregnancy, and lactation

No evidence found.

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Azetukalner

<a id="topic-2.1.2.9.1-1"></a>

###### CYP3A4 inhibition: itraconazole

> “In healthy subjects, a single 400 mg oral dose of the CYP3A4 inhibitor itraconazole given after 10 days of treatment with azetukalner (20 mg q.d.) was associated with an approximately 10% increase in peak plasma azetukalner concentration and a < 30% increase in azetukalner exposure”
> “Longer treatment with itraconazole, however, would be required to adequately assess the effect of CYP3A4 inhibition on azetukalner pharmacokinetics.”

Source: [Perucca and Taglialatela (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850491/)

<a id="topic-2.1.2.9.1-2"></a>

###### Modelled effect of CYP3A4 inhibitors and inducers

> “Modeling pharmacokinetic data from the phase 2b efficacy and safety study (see below) predicted a 32% increase in steady-state plasma azetukalner levels in the presence of CYP3A4 inhibitors. The same model predicted a 22% decrease in azetukalner exposure in the presence of concomitant treatment with a single CYP3A4 inducer, and a 39% decrease in the presence of two or more CYP3A4 inducers”

Source: [Perucca and Taglialatela (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850491/)

<a id="topic-2.1.2.9.1-3"></a>

###### Enzyme-inducing antiseizure medications and trial stratification

> “Azetukalner is primarily metabolized by cytochrome P450 3A4 (CYP3A4), with minimal involvement from other cytochrome P450 enzymes, and plasma levels of azetukalner may decrease in the presence of CYP3A4 inducers.”

Source: [French et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12014913/)

<a id="topic-2.1.2.9.1-4"></a>

###### Randomization stratified by enzyme-inducing background medication

> “XEN1101 is primarily metabolized by cytochrome P450 3A4 isozyme (CYP3A4) without substantial involvement of other CYPs, and plasma levels of XEN1101 may decrease in the presence of CYP3A4 inducers. To ensure balanced distribution across groups, randomization was stratified by background use of CYP3A4 inducer medications (eg, carbamazepine, eslicarbazepine acetate, oxcarbazepine, phenytoin, topiramate, or phenobarbital).”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

Additional sources: [ClinicalTrials.gov NCT03340220](https://clinicaltrials.gov/study/NCT03340220)

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Azetukalner on Other Drugs

<a id="topic-2.1.2.9.2-1"></a>

###### In vitro cytochrome P450 inhibition and induction

> “At in vitro concentrations of 3 μmol/L, which are much higher than those anticipated to be clinically efficacious, azetukalner did not cause direct inhibition of CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4, nor did it cause time-dependent inhibition”
> “Likewise, no clinically meaningful induction of the pregnane X nuclear receptor (PXR), which is associated with CYP3A4 expression levels, was observed at azetukalner concentrations of 0.1–1 μmol/L”

Source: [Perucca and Taglialatela (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850491/)

<a id="topic-2.1.2.9.2-2"></a>

###### Low potential for drug interactions in clinical use

> “A mechanism of action that differs from that of currently marketed ASMs and a low potential for drug–drug interactions make azetukalner a good candidate for adjunctive therapy in focal-seizure patients receiving any type of concomitant medication. Additional advantages include the feasibility of once daily dosing without titration.”

Source: [Perucca and Taglialatela (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850491/)

<a id="topic-2.1.2.9.2-3"></a>

###### No dose adjustment of concomitant antiseizure medications

> “Azetukalner has the potential to deliver much needed innovation to treat people living with focal seizures, with strong efficacy, a differentiated mechanism of action that may enable rational polytherapy, once-daily dosing with no dose adjustments for other antiseizure medications, and a consistent and generally well-tolerated safety profile”

Source: [Xenon Pharmaceuticals NDA submission release (2026)](https://www.globenewswire.com/news-release/2026/09/17/3364364/33485/en/xenon-announces-azetukalner-nda-submission-to-fda-for-focal-seizures-and-provides-update-on-psychiatry-clinical-program.html)

<a id="topic-2.1.2.9.2-4"></a>

###### Effect on hormonal contraceptives

No evidence found.

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### Doses evaluated in the Phase 3 focal seizure studies

> “The completed X-TOLE2 study and the ongoing X-TOLE3 study were both designed as multicenter, randomized, double-blind, placebo-controlled studies to evaluate the clinical efficacy, safety, and tolerability of 15 mg or 25 mg of azetukalner administered orally with food as adjunctive treatment in approximately 360 patients per study with FOS.”

Source: [Xenon Pharmaceuticals NDA submission release (2026)](https://www.globenewswire.com/news-release/2026/09/17/3364364/33485/en/xenon-announces-azetukalner-nda-submission-to-fda-for-focal-seizures-and-provides-update-on-psychiatry-clinical-program.html)

<a id="topic-2.1.2.10.1-2"></a>

###### No titration at initiation or tapering at discontinuation

> “Patients were randomized 2:1:1:2 to receive XEN1101, 25, 20, or 10 mg, or placebo with food once daily for 8 weeks. Dosage titration was not used.”
> “which enables gradual self-titration associated with a rapid onset of effect, with nearly the maximum seizure reduction achieved in each arm by the first week of treatment, which was sustained throughout the 8-week DBP in the 20- and 25-mg groups.”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-2.1.2.10.1-3"></a>

###### Dose used in long-term open-label treatment

> “Participants who completed the DBP with a minimum of 80% study medication compliance and no important protocol deviations were eligible to enter the OLE phase, during which participants from all DBP arms began treatment with azetukalner 20 mg taken once daily with food (Figure 1 ). Azetukalner dose adjustments and changes in concomitant ASMs were allowed during the OLE.”

Source: [French et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12014913/)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Oral once-daily administration with food

> “The X-TOLE2 clinical trial (NCT05614063) was a randomized, double-blind, placebo-controlled, multicenter Phase 3 study evaluating the efficacy, safety, and tolerability of azetukalner, administered as an oral, adjunctive therapy once-daily with food in adult patients with FOS.”

Source: [Xenon Pharmaceuticals X-TOLE2 topline release (2026)](https://www.globenewswire.com/news-release/2026/03/09/3251686/33485/en/Xenon-Announces-Positive-Topline-Data-from-Phase-3-X-TOLE2-Study-of-Azetukalner-in-Focal-Onset-Seizures-FOS.html)

<a id="topic-2.1.2.10.2-2"></a>

###### Rationale for administration with food and timing of the dose

> “XEN1101 was administered as a once-daily adjunctive treatment in capsule formulation by mouth. Because the oral bioavailability of XEN1101 is enhanced by coadministration with food, patients were instructed to take the study medication with the evening meal.”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-2.1.2.10.2-3"></a>

###### Administration in the Phase 3 studies

> “During the DBP, subjects will be instructed to orally take XEN1101 or placebo once daily with an evening meal.”

Source: [ClinicalTrials.gov NCT05614063](https://clinicaltrials.gov/study/NCT05614063)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Absence of an existing commercial and distribution infrastructure

> “We do not have a sales or marketing infrastructure and, as a company, have no sales, marketing or distribution experience. Our strategy involves building our own commercial infrastructure to selectively commercialize future products in certain commercial markets which will be expensive and time consuming. For certain products, including azetukalner, and/or specific commercial markets, we evaluate commercial partners from time to time.”

Source: [Xenon Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1582313/000119312526076650/xene-20251231.htm)

<a id="topic-2.1.2.11-2"></a>

###### Reliance on contract manufacturers for commercial supply

> “We do not own or operate manufacturing or testing facilities for the production of clinical or commercial quantities of our product candidates, and we lack the resources and the capabilities to do so. As a result, we currently rely on third parties for the manufacture and supply of the active pharmaceutical ingredients, or APIs, in our product candidates and the final drug product formulation”

Source: [Xenon Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1582313/000119312526076650/xene-20251231.htm)

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### Adjunctive use on a background of one to three antiseizure medications

> “Treatment with a stable dose of 1 to 3 allowable current ASMs for at least one month prior to screening, during baseline, and throughout the duration of the DBP”

Source: [ClinicalTrials.gov NCT05614063](https://clinicaltrials.gov/study/NCT05614063)

<a id="topic-2.1.2.12-2"></a>

###### Concomitant antiseizure medication use in the Phase 3 trial population

> “Participants had highly treatment-resistant epilepsy, with a median of five prior ASMs, a baseline seizure frequency of 12.75 per month, and 51.3% using three concomitant ASMs.”

Source: [Xenon Pharmaceuticals X-TOLE2 topline release (2026)](https://www.globenewswire.com/news-release/2026/03/09/3251686/33485/en/Xenon-Announces-Positive-Topline-Data-from-Phase-3-X-TOLE2-Study-of-Azetukalner-in-Focal-Onset-Seizures-FOS.html)

<a id="topic-2.1.2.12-3"></a>

###### Concomitant antiseizure medication use in the Phase 2b trial population

> “A total of 8.9% of the patients received 1 stable ASM at baseline and concomitantly throughout the DBP of the study, 40.6% of the patients received 2, and 50.5% of the patients received 3. Patients had tried and stopped a median of 6 previous ASMs before study entry. More than half of the patients (57.8%) were taking a CYP3A4 inducer at baseline.”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-2.1.2.12-4"></a>

###### Polytherapy in routine epilepsy management

> “Epilepsy is often managed with polytherapy – or concurrent use of multiple antiseizure medications (ASMs) – to improve seizure control. However, despite more than 30 available epilepsy treatments, up to half of people with focal epilepsy still live with uncontrolled seizures.”

Source: [Xenon Pharmaceuticals NDA submission release (2026)](https://www.globenewswire.com/news-release/2026/09/17/3364364/33485/en/xenon-announces-azetukalner-nda-submission-to-fda-for-focal-seizures-and-provides-update-on-psychiatry-clinical-program.html)

<a id="topic-2.1.2.12-5"></a>

###### Rationale for combining distinct mechanisms of action

> “Currently, healthcare professionals only have a handful of MOAs to choose from when treating epilepsy, and patients who do not respond to or tolerate an ASM with a specific MOA may be less likely to benefit from others with a similar MOA. Therefore, it is imperative that different MOAs be introduced to the treatment armamentarium to give more people living with epilepsy the opportunity to achieve seizure control.”

Source: [Xenon Pharmaceuticals EEC 2026 release (2026)](https://www.globenewswire.com/news-release/2026/08/26/3351670/33485/en/xenon-to-highlight-phase-3-x-tole2-clinical-data-and-rational-polytherapy-potential-for-azetukalner-at-eec-2026.html)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Azetukalner on Quality Measures

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Comparison with ezogabine: potency and daily dose

> “azetukalner was estimated to be approximately 50 times more potent than ezogabine”

Source: [Perucca and Taglialatela (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850491/)

<a id="topic-2.1.2.14-2"></a>

###### Comparison with retigabine: daily dose and metabolic burden

> “This is evident in the contrasting profiles of retigabine (600–1200 mg/day) and azetukalner (25 mg/day), where the significantly lower dose of azetukalner may reduce the burden on detoxification pathways.”

Source: [Rosendahl et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13330554/)

<a id="topic-2.1.2.14-3"></a>

###### Comparison with ezogabine: dosing schedule and tolerability limits of the predecessor

> “Ezogabine was approved for the treatment of focal seizures in 2011 but, because of the risk of pigmentary changes affecting the retina and the skin, and the consequent need for intensive ophthalmological monitoring, it was never used widely.”
> “One factor that probably contributed to ezogabine suboptimal tolerability was its short half-life, which results in considerable fluctuations in serum drug concentrations at steady state. The need for a t.i.d. regimen limited its acceptability in the clinical setting, and retention on treatment was generally lower than that reported for other second-generation ASMs”

Source: [Perucca and Taglialatela (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850491/)

<a id="topic-2.1.2.14-4"></a>

###### Comparison with retigabine: metabolic stability and brain penetration

> “This structural analog of retigabine exhibits improved metabolic stability, increased potency, and enhanced blood–brain barrier penetration compared with its predecessor.”

Source: [Rosendahl et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13330554/)

<a id="topic-2.1.2.14-5"></a>

###### Comparison with currently marketed antiseizure medications: confusional state

> “The most frequent TEAEs (dizziness, balance disorder, dysarthria, and gait disturbance) were related to the central nervous system and were similar to those associated with other commonly used ASMs. Some of these TEAEs were dose related and occurred at the highest dose. The adverse event of confusional state occurred at an overall rate of 4.7% in the treated group, which was 3.8% higher than placebo. These rates are similar to the frequencies of the rates observed in placebo-controlled phase 3 trials of lacosamide and oxcarbazepine, and less than the rates in trials of eslicarbazepine, pregabalin, perampanel, and topiramate.”

Source: [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)

<a id="topic-2.1.2.14-6"></a>

###### Mechanistic position relative to the available treatment armamentarium

> “Despite a large number of approved epilepsy treatments, there are only a handful of distinct mechanisms of action available, and the data from X-TOLE2 reinforce the value that azetukalner and its KV7 mechanism may bring to the treatment armamentarium for focal seizures”

Source: [Xenon Pharmaceuticals X-TOLE2 topline release (2026)](https://www.globenewswire.com/news-release/2026/03/09/3251686/33485/en/Xenon-Announces-Positive-Topline-Data-from-Phase-3-X-TOLE2-Study-of-Azetukalner-in-Focal-Onset-Seizures-FOS.html)

<a id="topic-2.1.2.14-7"></a>

###### Comparison with other potassium channel modulators in development

> “Related developments include BHV-7000 (BNP-25203), a KV7.2/7.3 modulator in phase II/III for both KCNQ2-DEE (precision use) and focal epilepsy; XEN496, a pediatric retigabine formulation repurposed as precision therapy for KCNQ2-DEE; and AUT-00206, a KV3.1/3.2 modulator in phase II for fragile X syndrome that enhances cortical network synchronization consistent with restored parvalbumin-interneuron function”

Source: [Martins (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13510719/)

<a id="topic-2.1.2.14-8"></a>

###### Direct comparison with another active antiseizure medication

No evidence found.

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Operational definition of epilepsy

> “Seizures are defined as transient symptoms and signs due to abnormal excessive or simultaneous neuronal activity of a population of neuronal cells in the brain.”
> “The diagnosis of epilepsy requires at least two unprovoked seizures occurring greater than twenty-four hours apart.”
> “Therefore, the definition of epilepsy has been revised and expanded from having two or more unprovoked seizures more than twenty-four hours apart to including those with one seizure and a high likelihood (more than 60%) of having another”
> “More than 60% was taken because it is the lower limit of the confidence interval for the individual with two unprovoked seizures having another seizure”

Source: [Sarmast et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7575300/)

<a id="topic-2.2.1.1-2"></a>

###### Resolved epilepsy

> “It is said to be resolved after ten years of the seizure-free period with the last five years spent without medications, or the patient is no longer at risk for age-related epilepsy syndrome”

Source: [Sarmast et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7575300/)

<a id="topic-2.2.1.1-3"></a>

###### Definition of focal seizures and the seizure classes

> “Focal seizures are defined as originating within networks limited to one hemisphere.”
> “They may be discretely localized or more widely distributed and may originate in cortical or subcortical structures.”
> “The updated classification maintains four main seizure classes: Focal, Generalized, Unknown (whether focal or generalized), and Unclassified.”
> “This updated classification comprises four main classes and 21 seizure types.”

Source: [Beniczky et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12169392/)

<a id="topic-2.2.1.1-4"></a>

###### Definition of drug-resistant epilepsy

> “Failure of adequate trials of two tolerated and appropriately chosen and used antiseizure medication (ASM) schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom”
> “The number of people for whom treatment fails to control their seizures remains at about 30%”

Source: [Auvin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10836613/)

<a id="topic-2.2.1.1-5"></a>

###### Predictors of drug resistance and its association with focal epilepsy

> “Some syndromes respond better to medication, e.g. the idiopathic generalized epilepsies or the childhood onset self-limited epilepsies which are less associated with resistance than the focal epilepsies or most of the DEEs.”
> “The two most robust epidemiological predictors of resistance are the number of previous ASMs tried (irrespective of the class of medication) and the number of seizures prior to starting medication, which is more likely a measure of disease severity rather than seizures influencing drug response.”

Source: [Auvin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10836613/)

<a id="topic-2.2.1.1-6"></a>

###### Etiologic categories

> “Etiology (structural, genetic, metabolic, infectious, immune, unknown)”

Source: [Sarmast et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7575300/)

<a id="topic-2.2.1.1-7"></a>

###### Age distribution of etiologies

> “Epilepsy incidence has a bimodal age distribution with the highest risk in infants (genetic, metabolic, and obstetrical causes) and older people (higher risk for stroke and neurodegenerative diseases)”

Source: [Ioannou et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9480957/)

Additional sources: [Fisher et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24730690/); [Fisher et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28276060/)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Focal onset seizures

<a id="topic-2.2.1.2.1-1"></a>

###### Incidence of focal compared with generalized seizures

> “Focal seizures are more common than generalized seizures.”
> “The median focal seizure incidence rate is 30.4 per 100,000 per year, compared to 19.6 per 100,000 per year for generalized seizures”
> “The most common type of focal seizures are focal impaired awareness seizures, accounting for approximately a third of all cases”

Source: [Ioannou et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9480957/)

<a id="topic-2.2.1.2.1-2"></a>

###### Estimated incidence of epilepsy among European adults

> “Epilepsy has an unequal distribution”
> “Based on the age-specific incidence rates in European studies, the estimated number of new cases per year among European adults aged 20−64 is 960,000 (incidence rate 30 per 100,000) and 85,000 in the ≥ 65 years population (incidence 100 per 100,000)”

Source: [Ioannou et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9480957/)

<a id="topic-2.2.1.2.1-3"></a>

###### Proportion of the epilepsy population with focal epilepsy

> “Focal epilepsy comprises about 55.7–61.1% of the overall epilepsy patient population.”

Source: [Gupta et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5719850/)

Additional sources: [Fiest et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27986877/)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Focal onset seizures

<a id="topic-2.2.1.2.2-1"></a>

###### United States prevalence of active epilepsy, 2015

> “In 2015, 1.2% of the U.S. population (3.4 million persons: 3 million adults and 470,000 children) reported active epilepsy (self-reported doctor-diagnosed epilepsy and under treatment or with recent seizures within 12 months of interview) or current epilepsy (parent-reported doctor-diagnosed epilepsy and current epilepsy).”

Source: [Zack and Kobau (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5687788/)

<a id="topic-2.2.1.2.2-2"></a>

###### United States prevalence of active epilepsy among adults, 2021

> “In 2021, 1.1% of U.S. adults, (approximately 2,865,000 adults) reported active epilepsy”

Source: [Kobau et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11034729/)

<a id="topic-2.2.1.2.2-3"></a>

###### Current national estimates of active epilepsy

> “CDC estimates that about 2.9 million U.S. adults had active epilepsy”
> “An estimated 456,000 U.S. children 17 or younger had active epilepsy in 2022”

Source: [CDC (2024)](https://www.cdc.gov/epilepsy/about/index.html)

<a id="topic-2.2.1.2.2-4"></a>

###### Treated prevalence of epilepsy and seizures in the United States, 2010 to 2018

> “Treated prevalence was .38% (95% confidence interval [CI] = .34–.41) for epilepsy, .76% (95% CI = .71–.81) for seizure, and 1.14% (95% CI = 1.08–1.20) for epilepsy or seizure.”

Source: [Moura et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10969856/)

<a id="topic-2.2.1.2.2-5"></a>

###### Global prevalence of active epilepsy

> “In 2016, there were 45·9 million (95% UI 39·9–54·6) patients with all-active epilepsy (both idiopathic and secondary epilepsy globally; age-standardised prevalence 621·5 per 100 000 population; 540·1–737·0).”
> “Prevalence of active epilepsy increased with age, with peaks at 5–9 years (374·8 [280·1–490·0]) and at older than 80 years of age (545·1 [444·2–652·0]).”

Source: [GBD 2016 Epilepsy Collaborators (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6416168/)

<a id="topic-2.2.1.2.2-6"></a>

###### Proportion of prevalent epilepsy that is focal

> “The prevalence of focal epilepsy was 3.70 per 1000, accounting for 61% of epilepsy”
> “Overall, estimates in 2016 for France, Germany, Italy, Spain, and the UK show that two-thirds of people with epilepsy had focal seizures, equating to over 1.3 million people”

Source: [Ioannou et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9480957/)

<a id="topic-2.2.1.2.2-7"></a>

###### Proportion of people with epilepsy who are drug resistant

> “approximately 40% of people with epilepsy are drug-resistant, further increasing the risks associated with epilepsy”

Source: [Ioannou et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9480957/)

<a id="topic-2.2.1.2.2-8"></a>

###### Persistent seizures among United States adults with focal epilepsy

> “The proportion of patients with persistent seizures (>1 per year) among AED users was higher in the U.S. (66.4%) than the 5EU (53.0%) and Brazil + 5EU (52.3%) datasets”

Source: [Gupta et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5719850/)

Additional sources: [Sultana et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33722992/)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Standardized mortality ratios in epilepsy

> “All of these nine showed significant elevations of their SMRs ranging from 1.6 to 3.0.”
> “Among six of these population-based studies representing incidence cohorts including all ages, the weighted median SMR was 2.3.”
> “Standard mortality ratios are especially high among people with epilepsy aged <50 years, among those whose epilepsy is categorized as structural/metabolic, those whose seizures do not fully remit under treatment, and those with convulsive seizures.”
> “Among deaths directly attributable to epilepsy or seizures, important immediate causes include sudden unexpected death in epilepsy (SUDEP), status epilepticus, unintentional injuries, and suicide.”

Source: [Thurman et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7004822/)

<a id="topic-2.2.1.3-2"></a>

###### Incidence of sudden unexpected death in epilepsy

> “SUDEP risk in children with epilepsy (aged 0–17 years) is 0.22/1,000 patient-years (95% CI 0.16–0.31) (high confidence in evidence). SUDEP risk increases in adults to 1.2/1,000 patient-years (95% CI 0.64–2.32) (low confidence in evidence).”
> “The major risk factor for SUDEP is the occurrence of generalized tonic-clonic seizures (GTCS); the SUDEP risk increases in association with increasing frequency of GTCS occurrence (high confidence in evidence).”
> “Clinicians should inform adult patients with epilepsy that SUDEP typically affects 1 in 1,000 adults with epilepsy per year; therefore, annually 999 of 1,000 adults will not be affected.”
> “Clinicians should inform persons with epilepsy that seizure freedom, particularly freedom from GTCS, is strongly associated with decreased SUDEP risk.”

Source: [Harden et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5486432/)

<a id="topic-2.2.1.3-3"></a>

###### Sudden unexpected death in epilepsy in treatment-resistant populations

> “Nine clinic-based studies, mainly representing people with treatment-resistant epilepsy, yielded higher estimates of SUDEP occurrence, ranging from 1.2 to 6.3 cases of SUDEP annually per 1,000 individuals.”

Source: [Thurman et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7004822/)

<a id="topic-2.2.1.3-4"></a>

###### Mortality by seizure control status in drug-resistant focal epilepsy

> “An Austrian study found that the standardized mortality ratio for those not seizure free was 3.3 (95% CI 2.6−4.4) compared to 1.4 (95% CI 0.8−2.3) for those seizure free 2 years after diagnosis”
> “Clinic-based studies report an estimate of SUDEP in people with drug-resistant focal epilepsy of up to 6.3 per 1000 people”
> “People with epilepsy are at a 27-fold higher risk of sudden death than controls, but this falls to a 16-fold risk when adjusted for sex, comorbidities, and the Charlson comorbidity score”

Source: [Ioannou et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9480957/)

<a id="topic-2.2.1.3-5"></a>

###### Seizure-related injury, drowning, and suicide

> “An observational study of people with epilepsy and convulsive seizures found that ∼60% of the population experienced at least one accidental injury associated with convulsions over 12 months; common injuries in this population included head injuries (35.5%), dental injuries (4.9%), and burns (4.9%)”
> “The risk of drowning is also higher in people with epilepsy, with an estimated relative risk ranging from 13- to 19-fold”
> “Attempted and completed suicides are estimated to occur in 5−14.3% of people with epilepsy”
> “the suicide-specific standardized mortality ratio among those with epilepsy is estimated to be 3.3 (95% CI: 2.8−3.7)”

Source: [Ioannou et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9480957/)

<a id="topic-2.2.1.3-6"></a>

###### Global mortality attributable to idiopathic epilepsy

> “Global age-standardised mortality rates of idiopathic epilepsy were 1·74 per 100 000 population (1·64–1·87; 1·40 per 100 000 population [1·23–1·54] for women and 2·09 per 100 000 population [1·96–2·25] for men).”

Source: [GBD 2016 Epilepsy Collaborators (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6416168/)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Neuronal hyperexcitability and epileptogenesis

> “Epilepsy represents a condition in which abnormal neuronal discharges or the hyperexcitability of neurons occur with synchronicity, presenting a significant public health challenge.”
> “This transformation presupposes the hyperexcitability of neuron groups, which become prone to discharge abnormally”

Source: [Boleti et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10813806/)

<a id="topic-2.2.1.4-2"></a>

###### Epileptiform synchronization in focal epileptic disorders

> “Intracellular recordings from neurons located in these foci demonstrated that interictal events were associated with paroxysmal depolarizing shifts (PDSs) of the neuron membrane potential causing bursts of action potential firing followed by a hyperpolarization”
> “These findings provide insights into the mechanisms of seizure initiation and maintenance, thus leading to the development of specific pharmacological treatments for focal epileptic disorders.”

Source: [Lévesque et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7052840/)

<a id="topic-2.2.1.4-3"></a>

###### Excitatory signaling in temporal lobe seizure generation

> “In contrast to NMDA receptors, which contribute but are not indispensable for seizure generation, AMPA receptors appear to be a key component to triggering seizures.”

Source: [Vismer et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4448038/)

<a id="topic-2.2.1.4-4"></a>

###### KV7 channels and the M-current in the control of neuronal excitability

> “Neuronal Kv7 channels underlie a voltage-gated non-inactivating potassium current known as the M-current.”
> “Due to its particular characteristics, Kv7 channels show pronounced control over the excitability of neurons.”
> “Kv7 channels locate to key areas for the control of action potential initiation and propagation.”
> “Finally, we will discuss the contribution of altered Kv7 activity to pathologies such as epilepsy and cognitive deficits.”

Source: [Greene and Hoshi (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5243414/)

Additional sources: [Shah et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4104618/)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Role and yield of routine electroencephalography

> “The electroencephalogram (EEG) is the most direct measure of electrical brain activity and the most specific test for the evaluation of epilepsy”
> “Patients most commonly receive a 20 min routine EEG recorded from 19 scalp electrodes placed according to the 10–20 electrode placement.”
> “Studies show that the initial routine EEG fails to record IEDs in approximately 47–50% of epileptic patients.”
> “To improve the yield of EEG, subsequent EEG recording should include sleep deprivation, sleep recording, prolonged hyperventilation, optimized light stimulation, addition of an inferior temporal electrode chain, extended EEG duration, and continuous video-EEG monitoring, all measures known to activate IEDs.”

Source: [Mesraoua et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12113856/)

<a id="topic-2.2.1.5-2"></a>

###### Role of magnetic resonance imaging

> “Similarly, magnetic resonance imaging (MRI) has become the gold standard imaging technique for identifying epileptogenic structural brain abnormalities.”

Source: [Mesraoua et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12113856/)

<a id="topic-2.2.1.5-3"></a>

###### Classification of focal seizures by state of consciousness

> “Focal seizures and those of unknown origin are further classified by the patient’s state of consciousness (impaired or preserved) during the seizure, defined operationally through clinical assessment of awareness and responsiveness.”
> “If the state of consciousness is undetermined, the seizure is classified under the parent term, that is, the main seizure class (focal seizure or seizure of unknown origin).”
> “Consciousness is used as a classifier instead of awareness, with consciousness operationally defined by awareness and responsiveness.”

Source: [Beniczky et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12169392/)

<a id="topic-2.2.1.5-4"></a>

###### Consistency of ictal onset in focal seizures

> “For each seizure type, ictal onset is consistent from one seizure to another, with preferential propagation patterns that may involve the contralateral hemisphere.”

Source: [Beniczky et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12169392/)

<a id="topic-2.2.1.5-5"></a>

###### Review of the diagnosis when seizures continue

> “Review the diagnosis of epilepsy if seizures continue despite an optimal dose of a first-line antiseizure medication.”

Source: [NICE guideline NG217 principles of treatment, safety monitoring and withdrawal (2022)](https://www.nice.org.uk/guidance/ng217/chapter/4-Principles-of-treatment-safety-monitoring-and-withdrawal)

<a id="topic-2.2.1.5-6"></a>

###### Assessments that trigger referral to a tertiary epilepsy service

> “further assessment and treatment approaches are indicated, such as: video electroencephalogram (EEG) telemetry, neuropsychology or neuropsychiatry, specialised neuroimaging, specialised treatments (for example, medication that can only be prescribed by a tertiary epilepsy service or a ketogenic diet), epilepsy surgery or vagus nerve stimulation”

Source: [NICE guideline NG217 referral to tertiary specialist services (2022)](https://www.nice.org.uk/guidance/ng217/chapter/3-Referral-to-tertiary-specialist-services)

<a id="topic-2.2.1.5-7"></a>

###### Investigations used to classify seizure type and epilepsy type

> “Classification of seizure type and epilepsy type both take into account the results of investigations such as electroencephalography (EEG) and neuroimaging studies together with other studies exploring the underlying etiology of the epilepsy.”

Source: [Scheffer et al. (2017)](https://www.epilepsydiagnosis.org/doc/Scheffer_et_al-2017-Epilepsia.pdf)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Seizure semiology: focal aware and focal impaired awareness seizures

> “Temporal lobe epilepsy (TLE) is the commonest form of focal epilepsy and represents almost 2/3 of cases of intractable epilepsy managed surgically.”
> “Seizure auras occur in many TLE patients and often exhibit features that are relatively specific for TLE but few are of lateralizing value.”
> “Automatisms represent coordinated involuntary motor activity that is stereotyped and virtually always accompanied by altered consciousness and subsequent amnesia.”
> “Automatisms occur in almost two thirds of CPSs of mesial temporal lobe onset”

Source: [Blair (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3420439/)

<a id="topic-2.2.1.6-2"></a>

###### Seizure semiology: focal to bilateral tonic-clonic seizures

> “focal seizures in which the ictal activity propagates to both hemispheres, while the semiology evolves to impairment and eventually complete loss of consciousness and bilateral tonic muscle activation”

Source: [Beniczky et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12169392/)

<a id="topic-2.2.1.6-3"></a>

###### Seizure semiology: ictal and postictal amnesia

> “Individuals with CPSs may be unaware that they had a seizure minutes earlier. They may also be unable to recall events which occurred before seizure onset. The degree of retrograde and anterograde amnesia is variable.”
> “Postictal amnesia likely results from bilateral impairment of hippocampal function.”

Source: [Blair (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3420439/)

<a id="topic-2.2.1.6-4"></a>

###### Cognitive symptoms: memory, executive function, and language impairment

> “The proportion with generalized cognitive impairment, another unexpected phenotype for a focal epilepsy, ranged from 15–44% (mean 29%), and the remaining individuals exhibited more focal cognitive patterns, involving reduced executive function and/or speed, and memory and/or language impairments”

Source: [Hermann et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8900353/)

<a id="topic-2.2.1.6-5"></a>

###### Cognitive symptoms: effect of seizures and medication on learning and memory

> “Aside from severe learning disabilities, epilepsy can impact learning through memory impairment. Seizures can reduce alertness and interfere with short-term information storage. Frequent uncontrolled or night-time seizures can impair new information learning, disrupt memory consolidation, and affect language function”
> “Cognitive impairments, such as learning difficulties, behavior change, and memory impairment, can be induced or exacerbated by ASMs, particularly those with impaired cognition, depending on dose and individual susceptibility”

Source: [Ioannou et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9480957/)

<a id="topic-2.2.1.6-6"></a>

###### Psychiatric symptoms: mood and anxiety disorders in newly diagnosed focal epilepsy

> “A total of 151 (43.5%) patients had a psychiatric diagnosis; 134 (38.6%) met the criteria for a mood and/or anxiety disorder, and 75 (21.6%) reported suicidal ideation with or without attempts.”
> “Mood (23.6%) and anxiety (27.4%) disorders had comparable prevalence rates, whereas both disorders occurred together in 43 patients (12.4%).”
> “In patients with newly diagnosed focal epilepsy, the prevalence of mood, anxiety disorders, and suicidality is higher than in the general population and comparable to those of patients with established epilepsy.”

Source: [Kanner et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10074468/)

<a id="topic-2.2.1.6-7"></a>

###### Psychiatric symptoms: pooled prevalence of depression in epilepsy

> “Nine studies reported on 29,891 PWE who had an overall prevalence of active (current or past-year) depression of 23.1% (95% confidence interval [CI] 20.6%–28.31%).”
> “Five of the 14 studies reported on 1,217,024 participants with an overall OR of active depression of 2.77 (95% CI 2.09–3.67) in PWE.”

Source: [Fiest et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3589287/)

<a id="topic-2.2.1.6-8"></a>

###### Psychiatric symptoms: other psychiatric comorbidity

> “The most prevalent psychiatric comorbidities are depression (23.1%) and anxiety (20.2%)”
> “People with epilepsy may also present with alcohol abuse (8.7%), drug abuse (7.8%), and interictal psychosis (5.2%)”

Source: [Ioannou et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9480957/)

Additional sources: [Scott et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28470748/)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Comorbidity burden in adults with active epilepsy

> “Approximately 50% of adults with active epilepsy have one or more comorbid conditions, with several conditions, such as depression, anxiety, dementia, migraine, heart disease, peptic ulcers, and arthritis being eight times more common in people with epilepsy compared to the general population”
> “Among people with intellectual disability, approximately one in five will also have epilepsy, with prevalence increasing with increasing severity of the intellectual disability”

Source: [Ioannou et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9480957/)

<a id="topic-2.2.1.7-2"></a>

###### Accelerated brain ageing and cognitive decline in drug-resistant epilepsy

> “A study found that people with DRE presented a difference between predicted brain age and chronological age that was on average 4.5 years older than healthy controls”
> “DRE is related to cognitive decline, and this phenomenon has been conceptualized as accelerated cognitive ageing”

Source: [Ioannou et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9480957/)

<a id="topic-2.2.1.7-3"></a>

###### Seizure-related injury in refractory focal epilepsy

> “Another US study found that hospitalization and pharmacy costs in people with focal seizures were twice as high in the refractory cohort versus the nonrefractory cohort. This was mainly due to the higher prevalence of injuries, including fractures, sprains and strains, and wounds”
> “People may injure themselves during a seizure resulting in fractures, head injury, sprains, and open wounds”

Source: [Ioannou et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9480957/)

<a id="topic-2.2.1.7-4"></a>

###### Employment and unemployment

> “Unemployment and underemployment are markedly more common in PwE compared with the general population.”
> “Unemployment rates range from similar to twice or three times the rates of the general population, depending on the countries and years examined.”
> “Developing specific legislation and programs to include PwE in the workplace could help their social integration.”

Source: [Narducci et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12011995/)

<a id="topic-2.2.1.7-5"></a>

###### Unemployment in drug-resistant focal seizures

> “Among people with drug-resistant focal seizures in Europe, high unemployment rates have been shown compared to a matched control population (46% vs. 19%)”
> “Productivity loss and unemployment among people with epilepsy are the primary sources of the individual and societal burden”

Source: [Ioannou et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9480957/)

<a id="topic-2.2.1.7-6"></a>

###### Driving restrictions

> “This consensus statement recommends that in order to be able to drive PWE should have a SFI of at least 3 months, but PWE with focal aware seizures, consistent and prolonged auras, or nocturnal seizures may still drive on a case-by-case basis.”
> “Due to unique state laws and variable physician awareness regarding these, patients may receive the wrong advice regarding driving.”

Source: [Joshi et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6891831/)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Focal onset seizures

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Instruments used to measure health-related quality of life in focal epilepsy

> “Ten instruments evaluating HRQOL in people with focal epilepsy were identified, of which four were epilepsy-specific”
> “HRQOL was also worse, often significantly so, in people with epilepsy and psychiatric disorders, particularly depression, than in those without psychiatric disorders.”

Source: [Boccaletti et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11633719/)

<a id="topic-2.2.1.8.1-2"></a>

###### Quality of life by treatment response in focal epilepsy

| Population | Quoted mean QOLIE-31-P total score with standard deviation |
| --- | --- |
| Focal epilepsy, drug resistant (n = 184) | “56.4 (18.7)” |
| Focal epilepsy, drug responsive (n = 53) | “70.8 (13.3)” |
| Comparison of the two groups | “<0.0001” |

Source: [Boccaletti et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11633719/)

<a id="topic-2.2.1.8.1-3"></a>

###### Stigma

> “Almost one quarter (23.8%) of people with epilepsy reported having felt enacted stigma”
> “Stigma was associated with family and social support and employment; with increasing perceptions of stigma associated with worse family functioning or unemployment/low employability.”
> “Perceived stigma was experienced similarly by both people with epilepsy and their caregivers.”

Source: [Boccaletti et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11633719/)

<a id="topic-2.2.1.8.1-4"></a>

###### Seizure freedom and quality of life

> “People seizure-free for more than 1 year have a significantly higher preference-based HRQoL than those in any other seizure frequency group.”
> “Further differentiation of QoL at higher response levels has been reported, with people achieving high response rates (particularly ≥90%) exhibiting higher QoL than people with ≤50% response rates”
> “This suggests that for a significant QoL improvement, seizure freedom must be attained and maintained”

Source: [Ioannou et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9480957/)

<a id="topic-2.2.1.8.1-5"></a>

###### Determinants of reduced quality of life

> “Some risk factors for reduced QoL have been identified, including frequent seizures, longer seizure duration, convulsions, and earlier age of onset”
> “Other factors affecting QoL include ASM side effects, depression or anxiety, lack of social support, stigma, and employment concerns”
> “Adults with epilepsy are likely to report more mentally and physically unhealthy days per month than those without epilepsy, with the highest rates in those with seizures in the past 3 months”

Source: [Ioannou et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9480957/)

<a id="topic-2.2.1.8.1-6"></a>

###### Health utilities by seizure frequency in United States adults with focal epilepsy

| Seizure frequency group, United States, unadjusted | Quoted mean SF-6D health utility with standard deviation |
| --- | --- |
| Total sample (n = 345) | “0.67 ± 0.14” |
| At least once a week (n = 55) | “0.63 ± 0.14” |
| One to three times a month (n = 68) | “0.65 ± 0.15” |
| One to four times a year (n = 71) | “0.67 ± 0.13” |
| Less than once a year (n = 151) | “0.70 ± 0.14” |
| p value for relationship to seizure frequency | “0.006” |

Source: [Gupta et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5719850/)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### United States aggregate spending attributable to epilepsy and seizures

> “The difference in annual spending for cases compared to controls was $4580 (95% CI = $3362–$5798) for epilepsy, $7935 (95% CI, $6237–$9634) for seizure, and $6853 (95% CI = $5623–$8084) for epilepsy or seizure, translating into aggregate costs of $5.4 billion, $19.0 billion, and $24.5 billion.”
> “From 2010 to 2018, the annual growth rate in total spending incurred for seizures and/or epilepsies was 7.6% compared to 3.6% among controls.”
> “US economic burden of seizures and/or epilepsies is substantial and warrants interventions focused on their unique and overlapping causes.”

Source: [Moura et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10969856/)

<a id="topic-2.2.1.8.2-2"></a>

###### United States spending for adults with epilepsy, 2016 to 2022

> “An estimated 6.6 million adults had unclassified seizures, with annual healthcare spending totaling $38.9 billion, substantially more than $21.3 billion for 4.5 million adults with epilepsy.”
> “Adults with unclassified seizures and epilepsy represent a high-need population with great healthcare use and costs.”

Source: [Rajadhyaksha et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12514382/)

<a id="topic-2.2.1.8.2-3"></a>

###### Cost of discrete epilepsy-related health care encounters in the United States

> “More than 160,000 epilepsy-related emergency transportations, 225,000 emergency department (ED) visits, 49,000 hospitalizations, 700 urgent care visits, and ~2.5 million office visits were analyzed.”
> “37.4% of epilepsy-related hospitalizations included care in the intensive care unit (ICU).”
> “In commercially insured patients, epilepsy-related health care encounters had median health plan-paid costs of $22,305 (Q1-Q3 = $14,336–$36,096, hospitalization); $3,375 ($565–$9,095, ICU visit); $1,913 ($417–$4,163, ED visit); $687 ($415–$1,083, emergency transportation); $95 ($23–$232, office visit); and $57 ($0–$171, urgent care visit).”

Source: [Borghs et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10390911/)

<a id="topic-2.2.1.8.2-4"></a>

###### Direct costs by seizure frequency in United States adults with focal epilepsy

| Seizure frequency group, United States, adjusted least-squares means | Quoted total direct costs in dollars with confidence interval |
| --- | --- |
| At least one seizure per week | “43,708 (28,420, 67,219)” |
| One to three seizures per month | “28,978 (19,665, 42,701)” |
| One to four seizures per year | “20,943 (14,497, 30,257)” |
| Less than one seizure per year | “18,600 (14,319, 24,162)” |
| Overall p value | “0.0008” |

Source: [Gupta et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5719850/)

<a id="topic-2.2.1.8.2-5"></a>

###### Association of seizure frequency with resource utilization in the United States

> “In the United States, seizure frequency was associated with hospitalizations, indirect costs (ages 18–60), and total direct costs.”
> “The results support the hypothesis that reducing seizures can improve productivity and reduce resource utilization and associated costs.”

Source: [Gupta et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5719850/)

<a id="topic-2.2.1.8.2-6"></a>

###### Incremental utilization and cost of uncontrolled and drug-resistant epilepsy

> “a US-based study estimated the odds of epilepsy-related hospitalization (OR: 2.2) and epilepsy-related emergency department visits (OR: 1.9) to be more significant for people with uncontrolled epilepsy; epilepsy-related costs were found to be ∼$6890/case/year higher for DRE”
> “The cost of epilepsy depends on seizure severity, frequency, and drug refractoriness (20% to 40% of people with drug-refractory epilepsy account for 80% of the costs).”
> “DRE incurs significantly higher resource utilization and costs than controlled epilepsy”

Source: [Ioannou et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9480957/)

<a id="topic-2.2.1.8.2-7"></a>

###### Overall direct cost of epilepsy in the United States

> “The direct costs of epilepsy have been estimated to be high (approximately $28 billion per year).”

Source: [Boccaletti et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11633719/)

Additional sources: [Begley and Durgin (2015)](https://pubmed.ncbi.nlm.nih.gov/26216617/)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Focal onset seizures on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Caregiver health care costs and absenteeism in focal onset seizures

> “Sick days were significantly lower in the monotherapy cohort (2.4 days vs 4.4 days annually; P <.0001), with an associated cost difference of $541.”
> “Caregivers of patients with partial-onset seizures in the adjunctive therapy cohort had significantly greater medical and sick day costs than caregivers in the monotherapy cohort.”
> “These findings suggest that higher treatment burden among patients with epilepsy is associated with greater direct and indirect healthcare costs for their caregivers.”

Source: [Brook et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6306097/)

<a id="topic-2.2.1.8.3-2"></a>

###### Caregiver work loss by treatment regimen

> “A 2018 study found that caregivers of people on monotherapy had an average of 2.7 days of work lost annually due to sick leave and short-term disability. In contrast, the caregivers to those on adjunctive therapy had an average of 5.1 days of work lost annually due to the same reasons”
> “Sick leave in caregivers of those on monotherapy was associated with average costs of $582; whereas, in the adjunctive therapy caregivers group, this increased to $1123.”

Source: [Ioannou et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9480957/)

<a id="topic-2.2.1.8.3-3"></a>

###### Caregiving time and caregiver distress

> “In a 2014 study in which 92% of people had focal seizures, a higher caregiver burden was associated with the individuals taking a higher number of ASMs, lower neuropsychological performance, lower QoL score, and lower caregiver education level.”
> “On average, 11.4 (±21.2) h were spent on care per week, with the majority (58.3%) of caregivers being a spouse/partner”
> “Caregivers of adults with epilepsy experience extreme psychological distress and poor QoL”
> “The results suggest that 72% of caregivers strongly agree that they fear another seizure, irrespective of when the last episode was.”

Source: [Ioannou et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9480957/)

<a id="topic-2.2.1.8.3-4"></a>

###### Caregiver productivity loss and health-related quality of life

> “Caregivers similarly reported high productivity loss and absenteeism related to caregiving duties.”
> “In another international cross-sectional study of caregivers of adults with uncontrolled drug-resistant focal-onset seizures, caregivers reported the greatest problems (moderate, severe, or extreme problems) in anxiety/depression (44% of caregivers) and pain/discomfort (40%).”

Source: [Boccaletti et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11633719/)

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

###### Comparative cost of ambulatory electroencephalography and inpatient video-electroencephalography monitoring

> “In a large retrospective cohort study of 13,958 patients, outpatient AEEG cost was significantly lower compared to inpatient VEM monitoring.”
> “These findings were similar to original economic models which indicated that AEEG was up to 66% cheaper than inpatient VEM”
> “Since January 1, 2020, in the United States, reimbursement for long-term inpatient EEG monitoring modified the fee structure for VEM and AEEG reimbursement for professional and technical components”

Source: [Tatum et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8578031/)

<a id="topic-2.2.1.8.4-2"></a>

###### Health care utilization before and after seizure monitoring unit admission, Canadian cohort

> “A total of 315 of 600 (53%) patients met eligibility criteria. Mean age was 40 years (SD = 17.4), 176 (56%) were female, 220 (70%) had focal epilepsy, and 60 (19%) had functional seizures or physiologic seizure mimics without epilepsy as adjudicated by the attending physician at the point of discharge.”
> “Admission to an SMU is associated with significant and enduring declines in HCU.”

Source: [Josephson et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11742541/)

<a id="topic-2.2.1.8.4-3"></a>

###### Diagnostic uncertainty as a cost driver

> “These findings highlight the impact of diagnostic uncertainty and care fragmentation, suggesting that improved identification and healthcare coordination could enhance outcomes and reduce inefficiencies.”

Source: [Rajadhyaksha et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12514382/)

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Sodium Channel Blockers

<a id="topic-2.2.2.1.1-1"></a>

###### First-line monotherapy for focal seizures

> “Consider lamotrigine or levetiracetam as first-line monotherapy for people with focal seizures. If the first choice is unsuccessful, consider the other of these options.”

Source: [NICE guideline NG217 treating epileptic seizures (2022)](https://www.nice.org.uk/guidance/ng217/chapter/5-Treating-epileptic-seizures-in-children-young-people-and-adults)

<a id="topic-2.2.2.1.1-2"></a>

###### Second-line and third-line monotherapy

> “They agreed that if these treatments were unsuccessful, carbamazepine, oxcarbazepine or zonisamide could be considered for second-line monotherapy. The evidence was weaker for lacosamide, so this was included as a third-line option.”
> “If second-line monotherapies tried are unsuccessful in people with focal seizures, consider lacosamide as third-line monotherapy.”

Source: [NICE guideline NG217 treating epileptic seizures (2022)](https://www.nice.org.uk/guidance/ng217/chapter/5-Treating-epileptic-seizures-in-children-young-people-and-adults)

<a id="topic-2.2.2.1.1-3"></a>

###### Comparative retention and tolerability evidence

> “The evidence showed that lamotrigine and levetiracetam were continued for longer than other drugs for treating focal epilepsy, suggesting that they may be more effective and better tolerated. However, the evidence also suggested they were not more effective than other drugs in terms of remission at 6 and 12 months, and the evidence for time to first seizure suggested they were less effective than carbamazepine.”

Source: [NICE guideline NG217 treating epileptic seizures (2022)](https://www.nice.org.uk/guidance/ng217/chapter/5-Treating-epileptic-seizures-in-children-young-people-and-adults)

<a id="topic-2.2.2.1.1-4"></a>

###### Initial monotherapy in new-onset adult focal epilepsy

> “Lamotrigine (LTG) should (Level B) and levetiracetam (LEV) and zonisamide (ZNS) may (Level C) be considered in decreasing seizure frequency in adults with new-onset focal epilepsy.”
> “LTG should (Level B) and gabapentin (GBP) may (Level C) be considered in decreasing seizure frequency in patients ≥60 years with new-onset focal epilepsy.”

Source: [Kanner et al. (2018a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6145382/)

<a id="topic-2.2.2.1.1-5"></a>

###### Adjunctive sodium channel blockers in treatment-resistant focal epilepsy

> “Lacosamide, eslicarbazepine, and extended-release topiramate use should also be considered to decrease seizure frequency in this population (Level B).”
> “Eslicarbazepine use may be considered to decrease seizure frequency as monotherapy for TRAFE (Level C).”

Source: [Kanner et al. (2018b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6145395/)

<a id="topic-2.2.2.1.1-6"></a>

###### Evidence levels for initial monotherapy for adult focal seizures

> “Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for adults with partial onset seizures.”
> “Selection of the initial AED therapy for a person with newly diagnosed or untreated seizures requires integration of evidence and expert opinion for the patient-specific, AED-specific, and nation-specific variables that can impact overall response to therapy.”

Source: [Glauser et al. (2013)](https://www.ilae.org/files/ilaeGuideline/Guidelines-epilepsia-12074-2013.pdf)

<a id="topic-2.2.2.1.1-7"></a>

###### Lamotrigine compared with levetiracetam and zonisamide in newly diagnosed focal epilepsy

> “Levetiracetam did not meet the criteria for non-inferiority in the ITT analysis of time to 12-month remission versus lamotrigine (HR 1·18; 97·5% CI 0·95–1·47)”
> “These findings do not support the use of levetiracetam or zonisamide as first-line treatments for patients with focal epilepsy.”
> “Lamotrigine should remain a first-line treatment for patients with focal epilepsy and should be the standard treatment in future trials.”
> “Adverse reactions were reported by 108 (33%) participants who started lamotrigine, 144 (44%) participants who started levetiracetam, and 146 (45%) participants who started zonisamide.”

Source: [Marson et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8047799/)

<a id="topic-2.2.2.1.1-8"></a>

###### Mechanistic basis of the sodium channel blocking class

> “Classical ASMs such as phenytoin, carbamazepine, oxcarbazepine (OXC), and lamotrigine preferentially bind to sodium channels in the inactivated state.”
> “Enhancement of slow inactivation of sodium channels by newer ASMs, such as lacosamide (LCM) and eslicarbazepine acetate (ESL), represents an innovative mechanism distinguishing them from classical VGSC blockers”

Source: [Rudkowska et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13509782/)

<a id="topic-2.2.2.1.1-9"></a>

###### Adjunctive lacosamide: pooled efficacy and withdrawal

> “The RR for a 50% or greater reduction in seizure frequency for all doses of lacosamide compared with placebo was 1.79 (95% CI 1.55 to 2.08; 5 studies; 2199 participants; high-certainty evidence).”
> “The RR for seizure freedom for all doses of lacosamide compared with placebo was 2.27 (95% CI 1.35 to 3.83; 5 studies; 2199 participants; low-certainty evidence).”
> “The RR for treatment withdrawal for all doses of lacosamide compared with placebo was 1.57 (95% CI 1.24 to 1.98; 5 studies; 2199 participants; moderate-certainty evidence).”

Source: [Babar et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8127139/)

<a id="topic-2.2.2.1.1-10"></a>

###### Adjunctive lacosamide: pivotal trial

> “Median percent reductions in seizure frequency per 28 days from baseline to maintenance (intention-to-treat, ITT) were 37.3% for lacosamide 400 mg/day (p = 0.008) and 37.8% for lacosamide 600 mg/day (p = 0.006) compared to 20.8% for placebo, with responder rates of 38.3% and 41.2%, respectively, compared to placebo (18.3%, p < 0.001; ITT).”

Source: [Chung et al. (2010a)](https://pubmed.ncbi.nlm.nih.gov/20132285/)

<a id="topic-2.2.2.1.1-11"></a>

###### Adjunctive lacosamide: seizure freedom in pooled trials

> “A total of 2.7%, 3.3% and 4.8% of patients completing the Maintenance Phase in the lacosamide 200, 400 and 600 mg/day groups, respectively, experienced no seizures throughout the entire Maintenance Phase (placebo group = 0.9%).”

Source: [Chung et al. (2010b)](https://pubmed.ncbi.nlm.nih.gov/21090838/)

<a id="topic-2.2.2.1.1-12"></a>

###### Adjunctive eslicarbazepine acetate: pooled efficacy

> “For adults, the RR was 1.71 (95% CI 1.42 to 2.05; 5 studies, 1799 participants; moderate-certainty evidence)”
> “ESL was associated with seizure freedom (RR 3.16, 95% CI 1.73 to 5.78; 6 studies, 1922 participants; moderate-certainty evidence).”
> “ESL reduces seizure frequency when used as an add-on treatment for adults with drug-resistant focal epilepsy.”

Source: [Chang et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8218144/)

<a id="topic-2.2.2.1.1-13"></a>

###### Adjunctive eslicarbazepine acetate: pivotal trial responder rate

> “Responder rate (≥50% reduction in SSF) was significantly higher with ESL 1,200 mg (42.6%, p < 0.001) but not ESL 800 mg (30.5%, p = 0.07) than placebo (23.1%).”
> “The most common TEAEs were dizziness, somnolence, nausea, headache, and diplopia.”

Source: [Sperling et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4354260/)

<a id="topic-2.2.2.1.1-14"></a>

###### Adjunctive oxcarbazepine: pooled efficacy

> “Oxcarbazepine may increase the responder rate for 50% or greater reduction in seizure frequency compared to control treatment (RR 1.80, 95% CI 1.27 to 2.56; random-effects model; 6 studies; low-certainty evidence).”
> “Treatment with oxcarbazepine was associated with an increased treatment withdrawal rate compared to control (RR 1.75, 95% CI 1.44 to 2.13; fixed-effect model; 6 studies; moderate-certainty evidence).”

Source: [Bresnahan et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7059897/)

<a id="topic-2.2.2.1.1-15"></a>

###### Adjunctive lamotrigine: pooled efficacy

> “The overall risk ratio (RR) for 50% or greater reduction in seizure frequency was 1.80 (95% CI 1.45 to 2.23; 12 trials, 1322 participants (adults and children); moderate-certainty evidence)”
> “Lamotrigine as an add-on treatment for drug-resistant focal seizures appears to be effective in reducing seizure frequency, and seems to be fairly well-tolerated.”

Source: [Panebianco et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7083514/)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 SV2A Ligands

<a id="topic-2.2.2.1.2-1"></a>

###### Levetiracetam as a first-line monotherapy option

> “The committee agreed that lamotrigine and levetiracetam should be considered as first-line monotherapy options, and this was supported by economic modelling.”

Source: [NICE guideline NG217 treating epileptic seizures (2022)](https://www.nice.org.uk/guidance/ng217/chapter/5-Treating-epileptic-seizures-in-children-young-people-and-adults)

<a id="topic-2.2.2.1.2-2"></a>

###### Mechanistic basis of the SV2A ligand class

> “Of them, levetiracetam and brivaracetam show a high affinity to the synaptic vesicle protein type 2 A (SV2A), whereas pregabalin and gabapentin are selective ligands for the α2δ1 subunits of the voltage-gated calcium channels.”

Source: [Czapińska-Ciepiela et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11294404/)

<a id="topic-2.2.2.1.2-3"></a>

###### Adjunctive levetiracetam: pooled efficacy and dose response

> “RR was significantly in favour of levetiracetam compared to placebo when results were pooled across all doses (RR 2.37, 95% CI 2.02 to 2.78; 14 studies, 2455 participants; moderate-certainty evidence).”
> “Dose–response analysis demonstrated that the odds of achieving response (50% or greater reduction in seizure frequency) were increased by nearly 40% (odds ratio (OR) 1.39, 95% CI 1.23 to 1.58) for each 1000 mg increase in dose of levetiracetam.”

Source: [Mbizvo et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7387854/)

<a id="topic-2.2.2.1.2-4"></a>

###### Adjunctive levetiracetam: pivotal placebo-controlled trial

> “Of 199 patients receiving levetiracetam, 11 became seizure free; no patient became seizure free in the placebo group.”

Source: [Cereghino et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10908898/)

<a id="topic-2.2.2.1.2-5"></a>

###### Adjunctive levetiracetam: European multicentre trial

> “A reduction in seizure frequency of > or =50% occurred in 22.8% of patients in the 1,000-mg group and 31.6% of patients in the 2,000-mg group, compared with 10.4% of patients in the placebo group.”

Source: [Shorvon et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10999557/)

<a id="topic-2.2.2.1.2-6"></a>

###### Adjunctive brivaracetam: pooled efficacy and withdrawal

> “Participants receiving brivaracetam add-on were more likely to experience a 50% or greater reduction in seizure frequency than those receiving placebo (RR 1.81, 95% CI 1.53 to 2.14; 6 studies; moderate-certainty evidence).”
> “Participants receiving brivaracetam were more likely to attain seizure freedom; however, the evidence is of low certainty (RR 5.89, 95% CI 2.30 to 15.13; 6 studies).”
> “However, participants receiving brivaracetam did appear to be more likely to withdraw from treatment due to adverse events compared with those receiving placebo (RR 1.54, 95% CI 1.02 to 2.33; 6 studies; low-certainty evidence).”

Source: [Bresnahan et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8919456/)

<a id="topic-2.2.2.1.2-7"></a>

###### Adjunctive brivaracetam: phase 3 trial

> “Percent reduction over PBO in 28-day adjusted seizure frequency (95% confidence interval [CI]) was 22.8% for BRV 100 mg/day (13.3-31.2%; p < 0.001) and 23.2% for BRV 200 mg/day (13.8-31.6%; p < 0.001).”
> “The ≥ 50% responder rate (odds ratio vs. PBO; 95% CI) was 21.6% for PBO, 38.9% for BRV 100 mg/day (2.39; 1.6-3.6; p < 0.001), and 37.8% for BRV 200 mg/day (2.19; 1.5-3.3; p < 0.001).”

Source: [Klein et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26471380/)

<a id="topic-2.2.2.1.2-8"></a>

###### Adjunctive brivaracetam: pooled phase 3 analysis

> “The ≥50% responder rate was 34.2% (50 mg/d, p = 0.0015), 39.5% (100 mg/d, p < 0.00001), and 37.8% (200 mg/d, p = 0.00003) vs 20.3% for placebo (p < 0.01).”
> “TEAEs in ≥5% patients taking BRV (vs placebo) were somnolence (15.2% vs 8.5%), dizziness (11.2% vs 7.2%), headache (9.6% vs 10.2%), and fatigue (8.7% vs 3.7%).”

Source: [Ben-Menachem et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4955277/)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Older Broad-spectrum Antiseizure Medications

<a id="topic-2.2.2.1.3-1"></a>

###### Position of valproate in the treatment sequence

> “Sodium valproate was moved to a third-line add-on treatment option for focal seizures.”

Source: [NICE guideline NG217 treating epileptic seizures (2022)](https://www.nice.org.uk/guidance/ng217/chapter/5-Treating-epileptic-seizures-in-children-young-people-and-adults)

<a id="topic-2.2.2.1.3-2"></a>

###### Pregnancy prevention conditions for valproate and topiramate

> “These antiseizure medications should not be used in women and girls of childbearing potential unless the conditions of the Pregnancy Prevention Programme are fulfilled.”

Source: [NICE guideline NG217 principles of treatment, safety monitoring and withdrawal (2022)](https://www.nice.org.uk/guidance/ng217/chapter/4-Principles-of-treatment-safety-monitoring-and-withdrawal)

<a id="topic-2.2.2.1.3-3"></a>

###### Efficacy levels of older broad-spectrum agents as initial monotherapy

> “CBZ, LEV, PHT, and ZNS are established (level A); VPA is probably (level B); GBP, LTG, OXC, phenobarbital (PB), TPM, and vigabatrin (VGB) are possibly (level C); whereas clonazepam (CZP) and primidone (PRM) are potentially (level D) efficacious/effective as initial monotherapy for adults with newly diagnosed or untreated partial-onset seizures.”

Source: [Glauser et al. (2013)](https://www.ilae.org/files/ilaeGuideline/Guidelines-epilepsia-12074-2013.pdf)

<a id="topic-2.2.2.1.3-4"></a>

###### Adjunctive topiramate: pooled efficacy and withdrawal

> “The RR for a 50% or greater reduction in seizure frequency with add-on topiramate compared to placebo was 2.71 (95% CI 2.05 to 3.59; 12 studies; high-certainty evidence).”
> “The proportion of participants achieving seizure freedom was also significantly increased with add-on topiramate compared to placebo (RR 3.67, 95% CI 1.79 to 7.54; 8 studies; moderate-certainty evidence).”
> “Treatment withdrawal was significantly higher for add-on topiramate compared to placebo (RR 2.37, 95% CI 1.66 to 3.37; 12 studies; high-certainty evidence).”

Source: [Bresnahan et al. (2019b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6806021/)

<a id="topic-2.2.2.1.3-5"></a>

###### Adjunctive zonisamide: pooled efficacy and withdrawal

> “The overall RR with 95% confidence interval (CI) for at least a 50% reduction in seizure frequency for 300 mg to 500 mg/day of zonisamide compared to placebo was 1.90 (95% CI 1.63 to 2.22; 7 trials, 1371 participants; moderate-certainty evidence).”
> “The number needed to treat for an additional beneficial outcome was six (95% CI 4.1 to 6.8).”
> “The RR for treatment withdrawal for 300 mg to 500 mg/day of zonisamide compared to placebo was 1.59 (95% CI 1.18 to 2.13; 6 trials, 1099 participants; moderate-certainty evidence)”

Source: [Brigo et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7389315/)

<a id="topic-2.2.2.1.3-6"></a>

###### Teratogenic risk restricting use

> “Valproate, phenobarbital, and topiramate increase the risk of major congenital malformations in babies born to people with epilepsy and should therefore be avoided in those planning to conceive or who are pregnant”

Source: [Löscher et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8408078/)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 AMPA Receptor Antagonists

<a id="topic-2.2.2.1.4-1"></a>

###### Perampanel in treatment-resistant adult focal epilepsy

> “For TRAFE, immediate-release PGB and PER are established as effective to reduce seizure frequency (Level A).”

Source: [Kanner et al. (2018b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6145395/)

<a id="topic-2.2.2.1.4-2"></a>

###### Mechanism and approved role of perampanel

> “Perampanel is a highly selective, non-competitive AMPA receptor antagonist that may exert its antiepileptic effect through selective inhibition of AMPA receptors”
> “as add-on treatment for people with focal epilepsy who are 12 years of age and older”

Source: [Bresnahan et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10103545/)

<a id="topic-2.2.2.1.4-3"></a>

###### Adjunctive perampanel: pooled efficacy and withdrawal

> “Compared with placebo, participants receiving perampanel were more likely to achieve a 50% or greater reduction in seizure frequency (RR 1.67, 95% CI 1.43 to 1.95; 7 trials, 2524 participants; high-certainty evidence).”
> “Compared to placebo, perampanel increased seizure freedom (RR 2.50, 95% CI 1.38 to 4.54; 5 trials, 2323 participants; low-certainty evidence)”
> “Participants treated with perampanel were more likely to withdraw from treatment due to adverse effects compared to those receiving placebo (RR 2.36, 95% CI 1.59 to 3.51; 7 trials, 2524 participants; low-certainty evidence).”
> “Add-on perampanel is effective at reducing seizure frequency and may be effective at maintaining seizure freedom for people with drug-resistant focal epilepsy.”

Source: [Bresnahan et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10103545/)

<a id="topic-2.2.2.1.4-4"></a>

###### Adjunctive perampanel: pivotal study 304

> “Using this intent-to-treat population over the double-blind phase, the median percent change in seizure frequency was -21.0%, -26.3%, and -34.5% for placebo and perampanel 8 and 12 mg, respectively (p = 0.0261 and p = 0.0158 for 8 and 12 mg vs placebo, respectively).”
> “Fifty percent responder rates during the maintenance period were 26.4%, 37.6%, and 36.1%, respectively, for placebo, perampanel 8 mg, and perampanel 12 mg; these differences were not statistically significant for 8 mg (p = 0.0760) or 12 mg (p = 0.0914).”

Source: [French et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3413761/)

<a id="topic-2.2.2.1.4-5"></a>

###### Adjunctive perampanel: pivotal study 305

> “The 50% responder rates (intent-to-treat analysis) were 14.7%, 33.3%, and 33.9%, respectively, for placebo, perampanel 8 mg, and perampanel 12 mg, with significant improvements over placebo for both perampanel 8 mg (p = 0.002) and 12 mg (p < 0.001).”

Source: [French et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/22905857/)

<a id="topic-2.2.2.1.4-6"></a>

###### Adjunctive perampanel: dose-ranging study 306

> “Median percent change in seizure frequency-the primary efficacy endpoint-was -10.7%, -13.6%, -23.3%, and -30.8% for placebo, perampanel 2, 4, and 8 mg/day, respectively.”
> “The corresponding 50% responder rates were 17.9%, 20.6%, 28.5%, and 34.9%.”

Source: [Krauss et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22517103/)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Cenobamate

<a id="topic-2.2.2.1.5-1"></a>

###### Position in the second-line add-on tier

> “If first-line add-on treatments tried are unsuccessful in people with focal seizures, consider 1 of the following second-line add-on treatment options:”
> “If the first choice is unsuccessful, consider the other second-line add-on options.”

Source: [NICE guideline NG217 treating epileptic seizures (2022)](https://www.nice.org.uk/guidance/ng217/chapter/5-Treating-epileptic-seizures-in-children-young-people-and-adults)

<a id="topic-2.2.2.1.5-2"></a>

###### Recommendation for use in drug-resistant focal onset seizures

> “Cenobamate is recommended as an option as an add-on treatment for focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy that has not been adequately controlled with at least 2 antiseizure medicines.”

Source: [NICE technology appraisal guidance TA753 recommendations (2021)](https://www.nice.org.uk/guidance/ta753/chapter/1-Recommendations)

<a id="topic-2.2.2.1.5-3"></a>

###### Adjunctive cenobamate: pooled efficacy

> “The overall RR for at least a 50% reduction in seizure frequency for add-on cenobamate at any dose compared to placebo was 2.17 (52% versus 24%, 95% CI 1.66 to 2.84; 2 studies, 605 participants; moderate-certainty evidence).”
> “The RR for seizure freedom for add-on cenobamate at any dose compared to placebo was 4.45 (16% versus 5%, 95% CI 2.25 to 8.78; 2 studies, 605 participants; moderate-certainty evidence).”
> “Add-on cenobamate is probably better than placebo in reducing the frequency of seizures by at least 50% and in achieving seizure freedom in adults with focal epilepsy uncontrolled by one or more concomitant ASMs (moderate level of certainty).”

Source: [Brigo and Lattanzi (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11292785/)

<a id="topic-2.2.2.1.5-4"></a>

###### Adjunctive cenobamate: pivotal placebo-controlled trial

> “Compared to placebo, cenobamate conferred a greater median percent seizure reduction (55.6% vs 21.5%; p < 0.0001)”
> “The responder rate (≥50% reduction in seizure frequency) was 50.4% for cenobamate and 22.2% for placebo (p < 0.0001).”
> “During maintenance, 28.3% of cenobamate-treated and 8.8% of placebo-treated patients were seizure-free.”

Source: [Chung et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7357293/)

<a id="topic-2.2.2.1.5-5"></a>

###### Adjunctive cenobamate: dose-response trial

> “Responder rates during the maintenance phase were 25% (26 of 102 patients) for the placebo group compared with 40% (41 of 102; odds ratio 1·97, 95% CI 1·08-3·56; p=0·0365) for the 100 mg dose group, 56% (55 of 98; 3·74, 2·06-6·80; p<0·0001) for the 200 mg dose group, and 64% (61 of 95; 5·24, 2·84-9·67; p<0·0001) for the 400 mg dose group.”
> “Treatment-emergent adverse events led to discontinuation in five (5%) patients in the placebo group, 11 (10%) in the 100 mg dose group, 15 (14%) in the 200 mg dose group, and 22 (20%) in the 400 mg dose group.”
> “One serious case of drug reaction with eosinophilia and systemic symptoms occurred in the 200 mg cenobamate group.”

Source: [Krauss et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31734103/)

<a id="topic-2.2.2.1.5-6"></a>

###### Adjunctive cenobamate: long-term open-label safety study

> “The ≥50% responder rate for the total treatment duration was 71.7% (172/240).”
> “Among all patients who received a dose of cenobamate in the maintenance phase (n = 214), 13.1% (28/214) and 40.2% (86/214) achieved 100% and ≥90% seizure reduction during their entire maintenance treatment duration (median = 29.5 months).”
> “Common treatment-emergent adverse events among all 240 patients included fatigue (34.6%), dizziness (32.1%), and somnolence (29.6%).”

Source: [Sperling et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9293007/)

<a id="topic-2.2.2.1.5-7"></a>

###### Network meta-analysis of third-generation adjunctive antiseizure medications

> “Sixteen trials (BRV: n = 3, CNB: n = 1, ESL: n = 4, LCM: n = 4, PER: n = 4) were included, overall enrolling 4507 patients randomised to add-on active treatments”
> “Cenobamate was associated with a higher rate of ≥ 50% seizure frequency reduction than BRV [odds ratio (OR) 2.02, 95% confidence interval (CI) 1.11–3.66], ESL (OR 1.93, 95% CI 1.07–3.48), LCM (OR 1.86, 95% CI 1.04–3.32), and PER (OR 2.07, 95% CI 1.16–3.70).”
> “Adjunctive cenobamate had the greatest likelihood of being the best option for the ≥ 50% and 100% seizure frequency reduction. Adjunctive brivaracetam and lacosamide had the highest probabilities of being the best-tolerated treatments.”

Source: [Lattanzi et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8843918/)

<a id="topic-2.2.2.1.5-8"></a>

###### Network meta-analysis of approved add-on antiseizure medications for focal epilepsy

> “All ASMs showed significantly higher ≥50% responder rate compared with placebo.”
> “Among treatments, significantly higher 100% responder rate was observed with cenobamate compared to eslicarbazepine (10.71; 95% CI: 1.56–323.9) and zonisamide (10.63; 95% CI: 1.37–261.2).”
> “Of the ASMs included, cenobamate had the greatest likelihood of allowing patients to attain seizure freedom.”

Source: [Zhang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11296132/)

<a id="topic-2.2.2.1.5-9"></a>

###### Network meta-analysis ranking by seizure response and seizure freedom

> “For seizure response, all ASMs were significantly superior to placebo, with RTG ranking highest, followed by CNB.”
> “For seizure freedom, BRV was highest-ranked, followed by CNB, with BRV 100 mg/d leading, followed by CNB 400 mg/d.”

Source: [Chen et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10915785/)

<a id="topic-2.2.2.1.5-10"></a>

###### Expert consensus on position in the treatment sequence

> “Cenobamate can be used after the failure of two antiseizure medications, rather than being reserved for later stages of treatment”
> “This manuscript aims to synthesize available clinical trial data, real-world studies, and expert opinions regarding the use of cenobamate, and to provide practical recommendations for its early introduction in patients with drug-resistant focal epilepsy, particularly following the failure of two adequately dosed ASMs.”

Source: [Labate et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12255636/)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Alpha-2-Delta Calcium Channel Ligands

<a id="topic-2.2.2.1.6-1"></a>

###### Pregabalin in treatment-resistant adult focal epilepsy

> “For TRAFE, immediate-release PGB and PER are established as effective to reduce seizure frequency (Level A).”

Source: [Kanner et al. (2018b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6145395/)

<a id="topic-2.2.2.1.6-2"></a>

###### Mechanistic basis of the alpha-2-delta ligand class

> “Of them, levetiracetam and brivaracetam show a high affinity to the synaptic vesicle protein type 2 A (SV2A), whereas pregabalin and gabapentin are selective ligands for the α2δ1 subunits of the voltage-gated calcium channels.”

Source: [Czapińska-Ciepiela et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11294404/)

<a id="topic-2.2.2.1.6-3"></a>

###### Adjunctive pregabalin: pooled efficacy

> “For the primary outcome, participants randomised to pregabalin were significantly more likely to attain a 50% or greater reduction in seizure frequency compared to placebo (RR 1.95, 95% CI 1.40 to 2.72, 9 trials, 2663 participants, low-certainty evidence).”
> “Pregabalin was significantly associated with seizure freedom (RR 3.94, 95% CI 1.50 to 10.37, 4 trials, 1125 participants, moderate-certainty evidence).”
> “For people with drug-resistant focal epilepsy, pregabalin when used as an add-on treatment was significantly more effective than placebo at producing a 50% or greater seizure reduction and seizure freedom.”

Source: [Panebianco et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8962962/)

<a id="topic-2.2.2.1.6-4"></a>

###### Comparative tolerability of gabapentin

> “The evidence suggested that lamotrigine, levetiracetam and gabapentin may have more tolerable adverse events than other drugs.”

Source: [NICE guideline NG217 treating epileptic seizures (2022)](https://www.nice.org.uk/guidance/ng217/chapter/5-Treating-epileptic-seizures-in-children-young-people-and-adults)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 GABAergic Medications

<a id="topic-2.2.2.1.7-1"></a>

###### Position in the third-line add-on tier

> “If second-line add-on treatments tried are unsuccessful in people with focal seizures, consider 1 of the following third-line add-on treatment options:”
> “If the first choice is unsuccessful, consider the other third-line add-on options.”

Source: [NICE guideline NG217 treating epileptic seizures (2022)](https://www.nice.org.uk/guidance/ng217/chapter/5-Treating-epileptic-seizures-in-children-young-people-and-adults)

<a id="topic-2.2.2.1.7-2"></a>

###### Vigabatrin and rufinamide in treatment-resistant focal epilepsy

> “VGB and RFN should be considered established as effective for decreasing seizure frequency in TRAFE (Level A) but are not first-line agents (retinopathy risk with VGB and modest benefit with RFN).”
> “Clobazam and OXC-XR use may be considered to decrease seizure frequency in TRAFE (Level C).”

Source: [Kanner et al. (2018b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6145395/)

<a id="topic-2.2.2.1.7-3"></a>

###### Vigabatrin is not first-line in new-onset focal epilepsy

> “VGB use appears to be less efficacious than CBZ-IR use and may not be offered (Level C); furthermore, toxicity profile precludes VGB use as first-line therapy”

Source: [Kanner et al. (2018a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6145382/)

<a id="topic-2.2.2.1.7-4"></a>

###### Adjunctive tiagabine: pooled efficacy and withdrawal

> “The overall risk ratio (RR) with 95% confidence intervals (CIs) for a 50% or greater reduction in seizure frequency (tiagabine versus placebo) was 3.16 (95% CI 1.97 to 5.07; 3 trials; 769 participants; high-certainty evidence).”
> “The RR for treatment withdrawal (tiagabine versus placebo) was 1.81 (95% CI 1.25 to 2.62; 3 trials, 769 participants; moderate-certainty evidence).”
> “Tiagabine reduced seizure frequency but was associated with some adverse effects when used as an add-on treatment in people with drug-resistant focal epilepsy.”

Source: [Bresnahan et al. (2019a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6953346/)

<a id="topic-2.2.2.1.7-5"></a>

###### Vigabatrin: mechanism, vision loss, and restricted distribution

> “Vigabatrin is an irreversible inhibitor of gamma-amino-butyric acid transaminase (GABA-T), an enzyme that degrades GABA, an inhibitory neurotransmitter.”
> “Vigabatrin can cause permanent bilateral concentric visual field constriction (ie, tunnel vision), which may lead to disability and reduced visual acuity.”
> “Vigabatrin is available only through a restricted program called the Risk Evaluation and Mitigation Strategy (REMS).”

Source: [Singh and Carson (2024)](https://www.ncbi.nlm.nih.gov/books/NBK557579/)

<a id="heading-2.2.2.1.8"></a>

###### 2.2.2.1.8 Epilepsy Surgery

<a id="topic-2.2.2.1.8-1"></a>

###### Referral for resective epilepsy surgery

> “Refer people with drug-resistant epilepsy, including those without identified MRI abnormalities, for consideration of assessment for resective epilepsy surgery:”
> “For adults, this should be to a tertiary epilepsy service.”

Source: [NICE guideline NG217 non-pharmacological treatments (2022)](https://www.nice.org.uk/guidance/ng217/chapter/8-Non-pharmacological-treatments)

<a id="topic-2.2.2.1.8-2"></a>

###### Role and outcomes of resective surgery

> “Epilepsy surgery is the treatment of choice for patients with drug-resistant seizures.”
> “Resective surgery can improve quality-of-life and cognitive outcomes and is the only treatment demonstrated to improve survival and reverse excess mortality attributed to drug-resistant epilepsy (DRE)”
> “Yet, referral for surgical evaluations is often delayed while palliative options are pursued, with significant adverse consequences due to increased morbidity and mortality associated with intractable epilepsy.”

Source: [Jehi et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9562030/)

<a id="topic-2.2.2.1.8-3"></a>

###### Timing of referral for surgical evaluation

> “Referral for a surgical evaluation should be offered to every patient with drug-resistant epilepsy (up to 70 years of age), as soon as drug-resistance is ascertained, regardless of epilepsy duration, sex, socioeconomic status, seizure type, epilepsy type (including epileptic encephalopathies), localization, and comorbidities”
> “A surgical referral should be considered for older patients with drug-resistant epilepsy who have no surgical contraindication, and for patients (adults and children) who are seizure-free on 1–2 anti-seizure medications (ASM)s but have a brain lesion in non-eloquent cortex”

Source: [Jehi et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9562030/)

<a id="topic-2.2.2.1.8-4"></a>

###### Randomized trial of surgery for temporal lobe epilepsy

> “At one year, the cumulative proportion of patients who were free of seizures impairing awareness was 58 percent in the surgical group and 8 percent in the medical group (P<0.001).”
> “In temporal-lobe epilepsy, surgery is superior to prolonged medical therapy.”
> “Four patients (10 percent) had adverse effects of surgery. One patient in the medical group died.”

Source: [Wiebe et al. (2001)](https://pubmed.ncbi.nlm.nih.gov/11484687/)

<a id="topic-2.2.2.1.8-5"></a>

###### Randomized trial of early surgery in newly intractable temporal lobe epilepsy

> “Zero of 23 participants in the medical group and 11 of 15 in the surgical group were seizure free during year 2 of follow-up”
> “Among patients with newly intractable disabling MTLE, resective surgery plus AED treatment resulted in a lower probability of seizures during year 2 of follow-up than continued AED treatment alone.”
> “Patients are typically referred for surgery after 20 years of seizures, often too late to avoid significant disability and premature death.”

Source: [Engel et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4821633/)

<a id="topic-2.2.2.1.8-6"></a>

###### Practice parameter on temporal lobe resection

> “A single Class I study and 24 Class IV studies indicate that the benefits of anteromesial temporal lobe resection for disabling complex partial seizures is greater than continued treatment with antiepileptic drugs, and the risks are at least comparable.”
> “For patients who are compromised by such seizures, referral to an epilepsy surgery center should be strongly considered.”

Source: [Engel et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/12601090/)

<a id="topic-2.2.2.1.8-7"></a>

###### Laser interstitial thermal therapy for mesial temporal lobe epilepsy

> “At both 1- and 2-years after LITT, 58.0% achieved Engel I outcomes.”
> “LITT is a viable treatment for mTLE in patients who have been properly evaluated at a comprehensive epilepsy center.”

Source: [Wu et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6551254/)

<a id="heading-2.2.2.1.9"></a>

###### 2.2.2.1.9 Neurostimulation

<a id="topic-2.2.2.1.9-1"></a>

###### Vagus nerve stimulation when surgery is not suitable

> “If resective epilepsy surgery is not suitable for a person with drug-resistant seizures, consider vagus nerve stimulation as an add-on treatment to antiseizure medication.”

Source: [NICE guideline NG217 non-pharmacological treatments (2022)](https://www.nice.org.uk/guidance/ng217/chapter/8-Non-pharmacological-treatments)

<a id="topic-2.2.2.1.9-2"></a>

###### Vagus nerve stimulation: guideline update on efficacy over time

> “A ≥50% seizure reduction occurred in 36.8% of patients at 1 year, 43.2% at 2 years, and 42.7% at 3 years.”
> “Median seizure reductions relative to baseline were 35% at 1 year, 44.3% at 2 years, and 44.1% at 3 years.”
> “VNS may be considered progressively effective in patients over multiple years of exposure (Level C).”
> “In adult patients receiving VNS for epilepsy, improvement in mood may be an additional benefit (Level C).”

Source: [Morris et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3854750/)

<a id="topic-2.2.2.1.9-3"></a>

###### Vagus nerve stimulation: pivotal randomized trial

> “Patients receiving high stimulation (94 patients, ages 13 to 54 years) had an average 28% reduction in total seizure frequency compared with a 15% reduction in the low stimulation group”
> “Vagus nerve stimulation is an effective and safe adjunctive treatment for patients with refractory partial-onset seizures.”

Source: [Handforth et al. (1998)](https://pubmed.ncbi.nlm.nih.gov/9674777/)

<a id="topic-2.2.2.1.9-4"></a>

###### Responsive neurostimulation: pivotal randomized trial

> “Seizures were significantly reduced in the treatment (-37.9%, n = 97) compared to the sham group (-17.3%, n = 94; p = 0.012) during the blinded period and there was no difference between the treatment and sham groups in adverse events.”
> “This study provides Class I evidence that responsive cortical stimulation is effective in significantly reducing seizure frequency for 12 weeks in adults who have failed 2 or more antiepileptic medication trials, 3 or more seizures per month, and 1 or 2 seizure foci.”

Source: [Morrell et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21917777/)

<a id="topic-2.2.2.1.9-5"></a>

###### Responsive neurostimulation: nine-year prospective outcomes

> “responder rate was 73%, and 35% had a ≥90% reduction in seizure frequency.”
> “We found that 18.4% (47 of 256) experienced ≥1 year of seizure freedom, with 62% (29 of 47) seizure-free at the last follow-up and an average seizure-free period of 3.2 years”
> “There were no serious AEs related to stimulation, and the sudden unexplained death in epilepsy (SUDEP) rate was significantly lower than predefined comparators”

Source: [Nair et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7538230/)

<a id="topic-2.2.2.1.9-6"></a>

###### Deep brain stimulation of the anterior nucleus of the thalamus: pivotal trial

> “In the last month of the blinded phase the stimulated group had a 29% greater reduction in seizures compared with the control group, as estimated by a generalized estimating equations (GEE) model (p = 0.002).”
> “By 2 years, there was a 56% median percent reduction in seizure frequency; 54% of patients had a seizure reduction of at least 50%, and 14 patients were seizure-free for at least 6 months.”

Source: [Fisher et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20331461/)

<a id="topic-2.2.2.1.9-7"></a>

###### Deep brain stimulation of the anterior nucleus of the thalamus: five-year follow-up

> “The median percent seizure reduction from baseline at 1 year was 41%, and 69% at 5 years.”
> “The responder rate (≥50% reduction in seizure frequency) at 1 year was 43%, and 68% at 5 years.”
> “In the 5 years of follow-up, 16% of subjects were seizure-free for at least 6 months.”
> “anterior thalamic stimulation is associated with a 69% reduction in seizure frequency and a 34% serious device-related adverse event rate at 5 years.”

Source: [Salanova et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4352097/)

<a id="topic-2.2.2.1.9-8"></a>

###### Deep brain stimulation of the anterior nucleus of the thalamus: seven-year follow-up

> “At 7 years, median seizure frequency percent reduction from baseline was 75% (p < .001), with no outcome differences related to prior vagus nerve stimulation or resective surgery.”
> “The most severe seizure type, focal to bilateral tonic-clonic, was reduced by 71%.”

Source: [Salanova et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33830503/)

<a id="heading-2.2.2.1.10"></a>

###### 2.2.2.1.10 Ketogenic Dietary Therapy

<a id="topic-2.2.2.1.10-1"></a>

###### Ketogenic diet in drug-resistant epilepsy

> “Consider a ketogenic diet under the guidance of a tertiary epilepsy specialist, in people with:”
> “drug-resistant epilepsy if other treatment options have been unsuccessful or are not appropriate.”

Source: [NICE guideline NG217 non-pharmacological treatments (2022)](https://www.nice.org.uk/guidance/ng217/chapter/8-Non-pharmacological-treatments)

<a id="topic-2.2.2.1.10-2"></a>

###### Ketogenic diet in adults with intractable epilepsy: meta-analysis

> “We identified 402 articles, of which, 16 studies including 338 patients met the inclusion criteria.”
> “The results of the meta-analysis showed that the combined efficacy rates of all the symptoms of seizure freedom, seizure reduction by 50% or more, and seizure reduction below 50% in adults with intractable epilepsy were 13%, 53%, and 27%, respectively.”

Source: [Liu et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5839310/)

<a id="topic-2.2.2.1.10-3"></a>

###### Recommendations for ketogenic dietary therapy in adults

> “Surveys were obtained from 20 medical institutions with >2,000 adult patients treated with KDTs for epilepsy or other neurologic disorders.”
> “KDTs may be safe and effective in treating adults with drug-resistant epilepsy, and there is emerging evidence supporting the use in other adult neurologic disorders and general medical conditions as well.”

Source: [Cervenka et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8610544/)

<a id="heading-2.2.2.1.11"></a>

###### 2.2.2.1.11 Limitations of Current Therapies

<a id="topic-2.2.2.1.11-1"></a>

###### Summary

Roughly one third of adults with epilepsy continue to have seizures despite available antiseizure medications. In a 30-year longitudinal cohort of participants with newly diagnosed epilepsy, 1,144 participants (63.7%) had been seizure free for the previous year or longer at the end of the study period, and the authors concluded that overall outcomes in newly diagnosed epilepsy have not improved despite the availability of many new medications with differing mechanisms of action. The yield of each successive medication falls steeply. Expressed as model-predicted probabilities, the first regimen gave a probability of seizure freedom of 50.5%, the second added 11.6%, the third added 4.1%, and from the fourth regimen onward each additional medication added approximately 1% or less. An earlier cohort in the same clinical setting reported that 222 of 470 previously untreated participants (47%) became seizure free on their first medication and 67 (14%) on a second or third, and that among participants with no response to the first medication only 11% subsequently became seizure free when the first failure was due to lack of efficacy, compared with 41% when it was due to intolerable side effects. A 2025 update reported that 64% of participants were seizure free, a proportion identical to that reported in the smaller 2000 study from the same setting.

Tolerability and interaction burden compound this efficacy ceiling. In up to a quarter of people, tolerability issues may lead to treatment discontinuation and harm adherence, and polypharmacotherapy further increases the risk of drug interactions and adverse events. Carbamazepine, phenobarbital, phenytoin, and primidone induce cytochrome P450 enzymes while valproic acid inhibits them, changing the serum concentrations of other antiseizure medications and of anticoagulants, oral contraceptives, antidepressants, antipsychotics, antimicrobial drugs, antineoplastic drugs, and immunosuppressants. Enzyme-inducing medications also affect sex hormone metabolism, vitamin D homeostasis, bone metabolism, and cholesterol synthesis, and reduce the effectiveness of hormonal contraceptives. Valproate, phenobarbital, and topiramate increase the risk of major congenital malformations, and in the United Kingdom valproate must not be prescribed to any woman or girl able to have children unless the conditions of the Pregnancy Prevention Programme are followed, because around 1 in 9 babies (11%) exposed in pregnancy will have a birth defect.

The only previously marketed potassium channel opener, ezogabine, also known as retigabine, is no longer available. Its United States label carried a warning that the product can cause retinal abnormalities with funduscopic features similar to those seen in retinal pigment dystrophies, restricted use to adults who had responded inadequately to several alternative treatments, and required baseline and six-monthly visual monitoring by an ophthalmic professional. Approximately 10% of participants in long-term clinical trials developed skin discoloration, generally after two or more years of treatment and at doses of 900 mg or greater, and retinal pigmentary abnormalities occurred in about one third of participants examined after approximately four years of treatment. The product was withdrawn from the United States market in 2017 after use declined, and the European Commission withdrew the marketing authorisation for Trobalt on 19 July 2018 at the request of the marketing authorisation holder, for commercial reasons.

Source: [Chen et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5885858/); [Kwan and Brodie (2000)](https://pubmed.ncbi.nlm.nih.gov/10660394/); [Kwan and Brodie (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11921996/); [Ioannou et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9480957/); [Löscher et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8408078/); [Johannessen and Landmark (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3001218/); [NICE guideline NG217 principles of treatment, safety monitoring and withdrawal (2022)](https://www.nice.org.uk/guidance/ng217/chapter/4-Principles-of-treatment-safety-monitoring-and-withdrawal); [MHRA (2025)](https://www.gov.uk/guidance/valproate-reproductive-risks); [FDA (2013)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022345s006lbl.pdf); [Perucca and Taglialatela (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850491/); [EMA (2018)](https://www.ema.europa.eu/en/medicines/human/EPAR/trobalt)

<a id="topic-2.2.2.1.11-2"></a>

###### Proportion of adults who remain uncontrolled on antiseizure medications

> “At the end of the study period, 1144 patients (63.7%) had been seizure free for the previous year or longer.”
> “More than one-third of patients experience epilepsy that remains uncontrolled.”
> “Despite the availability of many new AEDs with differing mechanisms of action, overall outcomes in newly diagnosed epilepsy have not improved.”
> “Despite the introduction of more than a dozen new AEDs in the past 2 decades, there remain no robust data to suggest improvement in treatment outcomes.”

Source: [Chen et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5885858/)

<a id="topic-2.2.2.1.11-3"></a>

###### Diminishing probability of seizure freedom with successive medication regimens

> “There were 820 patients who were seizure free 1 year or longer with the initial AED, so the predicted probability was 50.5% (95% CI, 47.9%-53.1%).”
> “If the first treatment failed, the second AED regimen only provided an additional 11.6% probability of seizure freedom (n = 208; 95% CI, 10.1%-13.1%; P < .001).”
> “If the first 2 drugs failed to control all seizures, the third AED regimen offered only a 4.1% additional probability of seizure freedom.”
> “From the fourth AED regimen onwards, each additional AED only added an approximate 1% or less probability of seizure freedom.”
> “As a result, our findings lend support to the definition of drug-resistant epilepsy as failure of 2 appropriately selected and tolerated AED regimens.”

Source: [Chen et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5885858/)

<a id="topic-2.2.2.1.11-4"></a>

###### Early identification of refractory epilepsy

> “More than 30 percent of patients with epilepsy have inadequate control of seizures with drug therapy, but why this happens and whether it can be predicted are unknown.”
> “Among 470 previously untreated patients, 222 (47 percent) became seizure-free during treatment with their first antiepileptic drug and 67 (14 percent) became seizure-free during treatment with a second or third drug.”
> “Among patients who had no response to the first drug, the percentage who subsequently became seizure-free was smaller (11 percent) when treatment failure was due to lack of efficacy than when it was due to intolerable side effects (41 percent) or an idiosyncratic reaction (55 percent).”

Source: [Kwan and Brodie (2000)](https://pubmed.ncbi.nlm.nih.gov/10660394/)

<a id="topic-2.2.2.1.11-5"></a>

###### Patterns of treatment response in newly diagnosed epilepsy

> “The chance of seizure freedom declined with successive drug regimens, most markedly from the first to the third and among patients with localization-related epilepsies.”
> “A total of 543 (49%) patients remained seizure-free on their first AED; 398 were treated with a second regimen (as monotherapy in 254, in combination with the first drug in 144), 146 (37%) of whom became seizure-free.”
> “Less than 2% of patients became seizure-free on subsequent regimens but a few did so on their sixth or seventh regimen.”

Source: [Brodie et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3348850/)

<a id="topic-2.2.2.1.11-6"></a>

###### Seizure freedom unchanged across three decades of new antiseizure medications

> “In this latest update, 64% of patients were seizure-free, a proportion identical to that reported in the earlier, smaller study undertaken in the same clinical setting and published in 2000.”
> “This lack of fundamental progress in treatment outcomes has underpinned the relentless search for the "magic bullet" that will result in long-term seizure freedom for the majority of people designated as having drug-resistant epilepsy.”

Source: [Kwan and Brodie (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11921996/)

<a id="topic-2.2.2.1.11-7"></a>

###### Goal of therapy and the proportion not achieving it

> “The goal of epilepsy therapy is the complete elimination of seizures; however, this is not achievable in about one-third of patients.”
> “Patient tolerability of adverse drug effects is integral to successful treatment”

Source: [Löscher et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8408078/)

<a id="topic-2.2.2.1.11-8"></a>

###### Tolerability burden and polypharmacotherapy in focal seizures

> “In up to a quarter of people, tolerability issues may lead to treatment discontinuation, as well as harming adherence”
> “People with epilepsy are frequently treated with polypharmacotherapy, which further increases the risk of drug to drug interactions and, thus, adverse events.”

Source: [Ioannou et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9480957/)

<a id="topic-2.2.2.1.11-9"></a>

###### Enzyme induction and inhibition among antiseizure medications

> “The older AEDs are susceptible to cause induction (carbamazepine, phenobarbital, phenytoin, primidone) or inhibition (valproic acid), resulting in a decrease or increase, respectively, in the serum concentration of other AEDs, as well as other drug classes (anticoagulants, oral contraceptives, antidepressants, antipsychotics, antimicrobal drugs, antineoplastic drugs, and immunosupressants).”
> “It should also be noted that enzyme-inducing AEDs affect endogenous biochemical pathways, as metabolism of sex hormones, vitamin D homeostasis and bone metabolism and cholesterol synthesis”

Source: [Johannessen and Landmark (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3001218/)

<a id="topic-2.2.2.1.11-10"></a>

###### Contraceptive interactions and long-term adverse effects

> “Be aware that some antiseizure medications, for example, carbamazepine, oxcarbazepine, phenytoin and topiramate, can impair the effectiveness of hormonal contraceptives.”
> “Enzyme-inducing medications in particular are associated with reduced bone density.”
> “Long-term side effects may include adverse effects on blood parameters or bone health, or changes in lipid metabolism.”

Source: [NICE guideline NG217 principles of treatment, safety monitoring and withdrawal (2022)](https://www.nice.org.uk/guidance/ng217/chapter/4-Principles-of-treatment-safety-monitoring-and-withdrawal)

<a id="topic-2.2.2.1.11-11"></a>

###### Regulatory restrictions on valproate in people who can become pregnant

> “Valproate must not be prescribed to any woman or girl able to have children unless the conditions of the Pregnancy Prevention Programme (PPP) are followed.”
> “In women who take valproate while pregnant, around 1 in 9 babies (11%) will have a birth defect.”

Source: [MHRA (2025)](https://www.gov.uk/guidance/valproate-reproductive-risks)

<a id="topic-2.2.2.1.11-12"></a>

###### Ezogabine: warning, restricted indication, and monitoring requirement

> “POTIGA can cause retinal abnormalities with funduscopic features similar to those seen in retinal pigment dystrophies, which are known to result in damage to the photoreceptors and vision loss.”
> “POTIGA is a potassium channel opener indicated as adjunctive treatment of partial-onset seizures in patients aged 18 years and older who have responded inadequately to several alternative treatments and for whom the benefits outweigh the risk of retinal abnormalities and potential decline in visual acuity.”
> “All patients taking POTIGA should have baseline and periodic (every 6 months) systematic visual monitoring by an ophthalmic professional.”
> “Approximately 10% of patients in long-term clinical trials developed skin discoloration, generally after 2 or more years of treatment and at higher doses (900 mg or greater) of POTIGA.”

Source: [FDA (2013)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022345s006lbl.pdf)

<a id="topic-2.2.2.1.11-13"></a>

###### Withdrawal of the only previously marketed potassium channel opener

> “Ezogabine (retigabine), the first Kv7.2/3 activator introduced in 2011 for the treatment of focal seizures, was withdrawn from the market in 2017 due to declining use after discovery of its association with pigmentation changes in the retina, skin, and mucosae.”
> “Overall, retinal pigmentary abnormalities occurred in about one-third of patients who had eye examinations after approximately 4 years of treatment, but they may be seen earlier”

Source: [Perucca and Taglialatela (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850491/)

<a id="topic-2.2.2.1.11-14"></a>

###### European withdrawal of the retigabine marketing authorisation

> “On 19 July 2018, the European Commission withdrew the marketing authorisation for Trobalt (retigabine) in the European Union (EU).”
> “The withdrawal was at the request of the marketing authorisation holder, Glaxo Group Ltd, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.”
> “Trobalt was granted marketing authorisation in the EU on 28 March 2011 for adjunctive treatment of partial onset seizures.”

Source: [EMA (2018)](https://www.ema.europa.eu/en/medicines/human/EPAR/trobalt)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary

The treatment position addressed by an adjunctive potassium channel opener is add-on therapy for adults whose focal onset seizures persist on existing antiseizure medications. Clinical practice guidance defines that position by the number of failed medications rather than by mechanism. The International League Against Epilepsy defines drug-resistant epilepsy as failure of adequate trials of two tolerated, appropriately chosen and used medication schedules, whether as monotherapy or in combination, to achieve sustained seizure freedom, and NICE adopts that definition. Approximately 30% of people with focal epilepsy have seizures that are not controlled by antiseizure medications. NICE directs that a single medication be used whenever possible, that an add-on treatment be considered when monotherapy is unsuccessful, and that when trials of add-on treatment do not reduce seizures the regimen chosen should be the one providing the best balance between effectiveness and tolerability.

Mechanistic diversity supports adding a new mechanism rather than a further agent from a class already used, since combining medications with various mechanisms of action appears more efficacious than combining medications sharing the same or comparable mechanisms. Expert consensus on the most recently approved adjunctive agent argues against reserving new mechanisms for late-stage use, recommending introduction after the failure of two adequately dosed antiseizure medications rather than at later stages of treatment. Azetukalner was studied in exactly this position: participants in X-TOLE2 had a median of five prior antiseizure medications, 51.3% were taking three concomitant medications, and approximately 40% were taking concomitant cenobamate.

The care setting is specialist outpatient neurology care with access to a tertiary or comprehensive epilepsy centre. NICE requires that all people with suspected or confirmed epilepsy have access to a tertiary epilepsy service via their specialist, and sets a four-week referral target when seizures are drug resistant or treatment causes intolerable side effects. The National Association of Epilepsy Centers recommends that all epilepsy centres regularly assess medication adherence and side effects as part of routine outpatient care, and regularly screen for drug-resistant epilepsy. Once-daily oral dosing with food, without titration and without dose adjustment of concomitant antiseizure medications, would place administration in the same setting as other oral adjunctive antiseizure medications.

Source: [Kwan et al. (2010)](https://www.ilae.org/files/ilaeGuideline/Definition-of-Drug-Resistant-Epilepsy-2009-1528-1167.2009.02397.pdf); [NICE guideline NG217 treating epileptic seizures (2022)](https://www.nice.org.uk/guidance/ng217/chapter/5-Treating-epileptic-seizures-in-children-young-people-and-adults); [Lado et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10962912/); [Czapińska-Ciepiela et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11294404/); [Labate et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12255636/); [Xenon Pharmaceuticals X-TOLE2 topline release (2026)](https://www.globenewswire.com/news-release/2026/03/09/3251686/33485/en/Xenon-Announces-Positive-Topline-Data-from-Phase-3-X-TOLE2-Study-of-Azetukalner-in-Focal-Onset-Seizures-FOS.html); [Xenon Pharmaceuticals AAN 2026 data release (2026)](https://www.globenewswire.com/news-release/2026/04/19/3276673/33485/en/Xenon-Presents-Azetukalner-Phase-3-X-TOLE2-Study-Results-and-48-Month-Long-term-Data-in-Focal-Onset-Seizures-at-2026-AAN-Annual-Meeting.html); [Xenon Pharmaceuticals NDA submission release (2026)](https://www.globenewswire.com/news-release/2026/09/17/3364364/33485/en/xenon-announces-azetukalner-nda-submission-to-fda-for-focal-seizures-and-provides-update-on-psychiatry-clinical-program.html)

<a id="topic-2.2.2.2-2"></a>

###### Principles of monotherapy and add-on treatment

> “Use a single antiseizure medication (monotherapy) to treat epilepsy whenever possible.”
> “If monotherapy is unsuccessful, consider trying an add-on treatment.”
> “If trials of add-on treatment do not result in a reduction in seizures, use the regimen that provides the best balance between effectiveness and tolerability of side effects.”

Source: [NICE guideline NG217 principles of treatment, safety monitoring and withdrawal (2022)](https://www.nice.org.uk/guidance/ng217/chapter/4-Principles-of-treatment-safety-monitoring-and-withdrawal)

<a id="topic-2.2.2.2-3"></a>

###### Rationale for combining medications with different mechanisms of action

> “It appears that combining ASMs with various mechanisms of action is more efficacious than using combinations of ASMs sharing the same or comparable mechanisms”

Source: [Czapińska-Ciepiela et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11294404/)

<a id="topic-2.2.2.2-4"></a>

###### Proportion of the focal epilepsy population that is drug resistant

> “Drug-resistant focal epilepsy, as defined by the International League Against Epilepsy (ILAE), is characterized by the failure to achieve seizure control despite the use of at least two appropriately chosen and adequately dosed antiseizure medications (ASMs).”
> “This condition affects approximately 30% of patients and represents a significant clinical challenge.”

Source: [Labate et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12255636/)

<a id="topic-2.2.2.2-5"></a>

###### Definition of drug-resistant epilepsy used in guidance

> “Epilepsy in which seizures persist and seizure freedom is very unlikely to be attained with further manipulation of antiseizure medication. Defined by the International League Against Epilepsy as 'failure of adequate trials of 2 tolerated and appropriately chosen and used antiseizure medication schedules (whether as monotherapy or in combination) to achieve sustained seizure freedom'.”

Source: [NICE guideline NG217 terms used in this guideline (2022)](https://www.nice.org.uk/guidance/ng217/chapter/Terms-used-in-this-guideline)

<a id="topic-2.2.2.2-6"></a>

###### Care setting: comprehensive epilepsy centres and outpatient monitoring

> “As such, national and international professional organizations advocate for comprehensive epilepsy centers to provide both routine and highly specialized care for people with epilepsy (PWE).”
> “All epilepsy centers should regularly assess patient medication adherence and side effects as part of routine outpatient care.”

Source: [Lado et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10962912/)

<a id="topic-2.2.2.2-7"></a>

###### Access to a tertiary epilepsy service

> “Ensure that all children, young people and adults with suspected or confirmed epilepsy have access to a tertiary epilepsy service, if needed, via their specialist.”
> “Refer people with epilepsy to a tertiary epilepsy service, to be seen within 4 weeks, if any of the following apply: uncertainty about the diagnosis or cause of epilepsy, the seizure type or epilepsy syndrome”

Source: [NICE guideline NG217 referral to tertiary specialist services (2022)](https://www.nice.org.uk/guidance/ng217/chapter/3-Referral-to-tertiary-specialist-services)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### Pretreatment seizure burden and early response as predictors

> “Patients who have many seizures before therapy or who have an inadequate response to initial treatment with antiepileptic drugs are likely to have refractory epilepsy.”
> “The prevalence of persistent seizures was higher in patients with symptomatic or cryptogenic epilepsy than in those with idiopathic epilepsy (40 percent vs. 26 percent, P=0.004) and in patients who had had more than 20 seizures before starting treatment than in those who had had fewer (51 percent vs. 29 percent, P<0.001).”

Source: [Kwan and Brodie (2000)](https://pubmed.ncbi.nlm.nih.gov/10660394/)

<a id="topic-2.2.2.3-2"></a>

###### Quantified effect of baseline seizure frequency and prior treatment failure

> “For each increase in the numbers of seizures in the year prior to treatment, there was a 6% decrease in likelihood of being seizure free at the last clinic visit.”
> “Epilepsy that was not successfully controlled with the first AED had 1.73 times greater odds of not responding to treatment for each subsequent medication regimen”

Source: [Chen et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5885858/)

<a id="topic-2.2.2.3-3"></a>

###### Course patterns and their predictability in newly diagnosed epilepsy

> “Most patients with newly diagnosed epilepsy had a constant course which could usually be predicted early. The chance of seizure freedom declined with successive drug regimens, most markedly from the first to the third and among patients with localization-related epilepsies.”
> “Outcome pattern A was observed in 408 (37%), pattern B in 246 (22%), pattern C in 172 (16%), and pattern D in 272 (25%) patients.”
> “This pattern of response was particularly impressive in patients with localization-related epilepsies, who should, therefore, be evaluated early for resective surgery.”

Source: [Brodie et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3348850/)

<a id="topic-2.2.2.3-4"></a>

###### Clinical predictors of pharmacoresistance

> “Those reporting more than 10 seizures prior to initiation of therapy were more than twice as likely to develop refractory epilepsy.”
> “Univariate and multivariate logistic regression analyses demonstrated that pharmacoresistance was also associated with family history of epilepsy, previous febrile seizures, traumatic brain injury as the cause of the epilepsy, intermittent recreational drug use, and prior or current psychiatric comorbidity, particularly depression.”
> “Factors not predicting poorer outcome included gender, neurological deficit and mental retardation.”

Source: [Hitiris et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17628429/)

<a id="topic-2.2.2.3-5"></a>

###### Structural etiology as a determinant of seizure control

> “Seizure control (>1 year without seizure) was achieved in 82% of patients who had idiopathic generalized epilepsy, 35% of those with symptomatic partial epilepsy, 45% of those with cryptogenic partial epilepsy, and 11% of those with partial epilepsy associated with hippocampal sclerosis (HS).”
> “In partial epilepsy, HS, cerebral dysgenesis, and dual pathology (HS and another lesion) were associated with a low rate of seizure-free patients (11%, 24%, and 3%, respectively).”

Source: [Semah et al. (1998)](https://pubmed.ncbi.nlm.nih.gov/9818842/)

<a id="topic-2.2.2.3-6"></a>

###### Pharmacogenomic predictor of carbamazepine hypersensitivity

> “HLA-B*15:02 is specific for carbamazepine- and oxcarbazepine-induced SJS and TEN, though the data are strongest for carbamazepine.”
> “The FDA label for carbamazepine carries a boxed warning about the risk of SJS/TEN with the presence of the HLA-B*15:02 allele”

Source: [Phillips et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5847474/)

<a id="topic-2.2.2.3-7"></a>

###### Adjunctive efficacy by number of previously used antiseizure medications

> “Adjunctive BRV showed efficacy and was generally well tolerated in adults with focal seizures independent of the number of previous ASMs.”
> “The 50% responder rate was 26.9%, 29.9%, 30.0%, and 29.7% for BRV 50, 100, 200, and 50-200 mg/day, respectively (placebo: 13.2%); odds ratios versus placebo were statistically significant (p < 0.05) for BRV 100, 200, and 50-200 mg/day.”

Source: [Lee et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34155568/)

<a id="topic-2.2.2.3-8"></a>

###### Real-world seizure freedom by timing of adjunctive treatment

> “Sustained seizure freedom was achieved by 22.4% (n = 17) of early users and 8.7% (95% CI: 5.8–12.3, n = 27) of late users”

Source: [Lattanzi et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12291020/)

<a id="topic-2.2.2.3-9"></a>

###### Azetukalner response by baseline disease severity

> “Overall, 14.9% (n=114) in the placebo group and 54.5% (n=112) in the XEN1101 25-mg group achieved RR50. With XEN1101 treatment, RR50 was achieved by 65.5% of patients with ≤8.5 seizures per month at baseline (n=29) and 50.6% with >8.5 seizures per month (n=83), 64.2% of patients with ≤6 prior ASMs (n=67) and 40.0% with >6 ASMs (n=45), and 56.9% of patients with one to two concomitant ASMs (n=58) and 51.9% with three concomitant ASMs (n=54).”
> “XEN1101 was relatively more effective in patients with indicators of less-severe disease in the trial population. These findings suggest that XEN1101 may be appropriate for use in patients with focal epilepsy across the spectrum of disease severity.”

Source: [Porter et al. (2023)](https://aesnet.org/abstractslisting/the-impact-of-disease-severity-on-responder-rates-in-a-phase-2b-study-of-xen1101-a-potent-selective-potassium-channel-opener-in-adults-with-focal-epilepsy-x-tole)

Additional sources: [Bonnett et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22377180/); [Karnes et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7831382/)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Adherence to antiseizure medications and interventions to improve it

> “Poor adherence to antiepileptic medication is associated with increased mortality, morbidity and healthcare costs.”
> “We included 20 studies reporting data on 2832 participants.”
> “Behavioural interventions such as intensive reminders and the use of mixed interventions demonstrate some positive results, however, we need more reliable evidence on their efficacy, derived from carefully-designed RCTs before we can draw a firm conclusion.”

Source: [Al-aqeel et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8092477/)

<a id="topic-2.2.2.4-2"></a>

###### Consequences of nonadherence to antiseizure medications

> “Nonadherence was associated with an over threefold increased risk of mortality compared to adherence (hazard ratio = 3.32, 95% CI = 3.11-3.54) after multivariate adjustments.”
> “Time periods of nonadherence were also associated with a significantly higher incidence of ED visits (IRR = 1.50, 95% CI = 1.49-1.52), hospital admissions (IRR = 1.86, 95% CI = 1.84-1.88), MVA injuries (IRR = 2.08, 95% CI = 1.81-2.39), and fractures (IRR = 1.21, 95% CI = 1.18-1.23) than periods of adherence.”
> “These findings suggest that nonadherence to antiepileptic drugs can have serious or fatal consequences for patients with epilepsy.”

Source: [Faught et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18565827/)

<a id="topic-2.2.2.4-3"></a>

###### Service models: specialist epilepsy nurses and self-management education

> “Two intervention types, the specialist epilepsy nurse and self management education, have some evidence of benefit.”
> “At present it is not possible to advocate any single model of service provision.”

Source: [Bradley et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7390263/)

<a id="topic-2.2.2.4-4"></a>

###### Recommendations for specialized epilepsy centers

> “The panel reached consensus on 52 recommendations covering services provided by specialized epilepsy centers in both the inpatient and outpatient settings”
> “All epilepsy centers should regularly screen patients for drug-resistant epilepsy and refer such patients to multidisciplinary surgical conference for consideration of epilepsy surgery.”
> “Telemedicine is an important resource, providing earlier access to specialized care and improving patient satisfaction, especially in resource-limited areas.”

Source: [Lado et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10962912/)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Goal of antiseizure therapy

> “The goal of epilepsy therapy is the complete elimination of seizures; however, this is not achievable in about one-third of patients.”

Source: [Löscher et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8408078/)

<a id="topic-2.2.2.7-2"></a>

###### Operational definition of seizure freedom

> “seizure freedom (Category 1 outcome) is defined as freedom from seizures for a minimum of three times the longest preintervention interseizure interval (determined from seizures occurring within the past 12 months) or 12 months, whichever is longer.”
> “It is proposed as a testable hypothesis that drug resistant epilepsy is defined as failure of adequate trials of two tolerated, appropriately chosen and used antiepileptic drug schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom.”

Source: [Kwan et al. (2010)](https://www.ilae.org/files/ilaeGuideline/Definition-of-Drug-Resistant-Epilepsy-2009-1528-1167.2009.02397.pdf)

<a id="topic-2.2.2.7-3"></a>

###### Clinically accepted benchmark used by the manufacturer

> “The clinically accepted definition of seizure freedom is no seizures for at least 12 months.”

Source: [Xenon Pharmaceuticals AAN 2026 data release (2026)](https://www.globenewswire.com/news-release/2026/04/19/3276673/33485/en/Xenon-Presents-Azetukalner-Phase-3-X-TOLE2-Study-Results-and-48-Month-Long-term-Data-in-Focal-Onset-Seizures-at-2026-AAN-Annual-Meeting.html)

<a id="topic-2.2.2.7-4"></a>

###### What constitutes unsuccessful treatment

> “Treatment is unsuccessful if it does not reduce or stop seizures, or if side effects are intolerable for the person with epilepsy.”

Source: [NICE guideline NG217 terms used in this guideline (2022)](https://www.nice.org.uk/guidance/ng217/chapter/Terms-used-in-this-guideline)

<a id="topic-2.2.2.7-5"></a>

###### The responder endpoint used in adjunctive trials

> “Another widely used efficacy endpoint for evaluating ASM efficacy is the percentage of patients with a ≥50% reduction in seizure frequency during a given treatment period compared with baseline, known as the RR50.”

Source: [Porter et al. (2023)](https://aesnet.org/abstractslisting/the-impact-of-disease-severity-on-responder-rates-in-a-phase-2b-study-of-xen1101-a-potent-selective-potassium-channel-opener-in-adults-with-focal-epilepsy-x-tole)

<a id="topic-2.2.2.7-6"></a>

###### Seizure freedom rather than seizure reduction drives quality of life

> “In this study, HRQOL improvement occurred primarily among patients who achieved complete seizure freedom.”
> “Many AED trials use a 50% seizure-frequency reduction criterion as a trial end point, but measurable impacts of this degree of reduction in seizure frequency on HRQOL in this sample were not observed.”
> “No significant change in QOLIE-31 and QOLIE-89 overall scores was observed for subjects who did not achieve seizure freedom.”
> “These results further support striving for seizure freedom as an epilepsy care goal.”

Source: [Birbeck et al. (2002)](https://pubmed.ncbi.nlm.nih.gov/12027916/)

<a id="topic-2.2.2.7-7"></a>

###### Statistical limitations of the 50 percent responder criterion

> “We showed that individual variance in monthly seizure rates can lead to an unacceptably high false-positive rate in the detection of individual treatment responders.”
> “This finding suggests that some drugs may be incorrectly evaluated as effective; or, conversely, that helpful drugs could be rejected based on 50% response rates.”

Source: [Karoly et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31471901/)

<a id="topic-2.2.2.7-8"></a>

###### Seizure control and sudden unexpected death in epilepsy

> “Clinicians should inform persons with epilepsy that seizure freedom, particularly freedom from GTCS, is strongly associated with decreased SUDEP risk.”

Source: [Harden et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5486432/)

Additional sources: [FDA (2018)](https://www.fda.gov/media/110916/download)

## Related pages
- [Azetukalner (XEN1101): Focal onset seizures](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures) · [Markdown](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures.md)
- [Azetukalner (XEN1101) in Focal onset seizures: Terms and abbreviations](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/terms-and-abbreviations.md)
- [Azetukalner (XEN1101): Focal onset seizures](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/executive-summary) · [Markdown](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/executive-summary.md)
- [Azetukalner (XEN1101) in Focal onset seizures: Clinical evidence](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/clinical-evidence.md)
- [Azetukalner (XEN1101) in Focal onset seizures: Economic information and modeling report](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/economics) · [Markdown](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/economics.md)
- [Azetukalner (XEN1101) in Focal onset seizures: References](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/references) · [Markdown](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/references.md)
- [Azetukalner (XEN1101) in Focal onset seizures: prevalence by geography](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/prevalence) · [Markdown](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/prevalence.md)
- [Azetukalner (XEN1101) in Focal onset seizures: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/cost-effectiveness-analyses.md)
